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Metastatic melanoma is a highly aggressive cancer with a very poor prognosis and current 
therapies remain inadequate. Norway is among the top five countries with the highest incidence 
of melanoma.  
Malignant cells carry oncogenic mutations that engender uncontrolled growth and elicit 
activation of epithelial-to-mesenchymal transition (EMT), an embryonic gene program that 
induces cancer stem cell features, invasiveness, survival, chemotherapeutic resistance, immune 
modulation and metastasis. The receptor tyrosine kinase, Axl, is upregulated with this EMT 
program and overexpressed in several human cancers. Axl is upregulated in a subset of more 
invasive tumors and thought to be an important facilitator of resistance to therapeutics targeted 
against oncogenic RTKs. Activation of Axl is dependent on the binding of its ligand Gas6. Gas6 
is a vitamin K dependent protein that is modified by the γ-carboxylation of glutamic acid 
residues in the N-terminal Gla domain. Vitamin K serves as the cofactor for the enzyme γ-
glutamyl carboxylase (GGCX) that catalyzes the γ-carboxylation of the glutamic acid residues.  
BGB324 is an Axl kinase inhibitor currently in ongoing clinical trial against different types of 
cancers. 
Here we first characterized the expression of Axl, Gas6 and vitamin K enzymes such as GGCX 
in 20 melanoma cell lines and determine their correlation with clinical outcome. Our results 
suggest that GGCX but not Axl and Gas6 expression correlates with poor patient prognosis. 
We further evaluated the effect of vitamin K and BGB324 on 5 selected cell lines.  We found 
that the vitamin K increases the expression of Axl and other TAM receptors, GGCX and EMT-
related genes while when treated with BGB324 expression reduced or remained unchanged. 
However, BGB324 was not able to elicit this effect if the cells were cultured in vitamin K 
suggesting acquisition of a resistant phenotype. We also evaluated the effect of vitamin K on 
NZM cell proliferation, migration and spheroid formation. Finally, we show that vitamin K 







Akt     Protein kinase B (PKB) 
APC    Adenomatous polyposis coli                                    
BSA     Bovine serum albumin 
CIM     Cell invasion/migration 
CML                                      Chronic Myelogenous Leukemia  
CTLA4   Anti-cytotoxic T lymphocyte antigen-4 
DMSO    Dimethyl sulfoxide 
ECM                                   Extracellular Matrix  
EGF                                       Epidermal Growth Factor  
EMT                                      Epithelial to Mesenchymal Transition  
EGFR                                     Epidermal Growth Factor Receptor  
HIF1     Hypoxia-inducible factor 1-alpha 
EPHX1                                  Epoxide Hydrolase 1  
GAPDH    Glyceraldehyde 3-phosphate dehydrogenase 
GAS6                                     Growth Arrest-Specific 6  
GDP                                       Guanosine Diphosphate  
GGCX                                    Gamma-Glutamyl Carboxylase  
Gla                                          Gamma-Carboxyglutamic Acid  
GTP                                        Guanosine Triphosphate 
Grb2    Growth factor receptor-bound protein 2  
HCC     Hepatocellular carcinoma 
HER2     Human epidermal growth factor receptor 2 
LDH    Lactate dehydrogenase 
MAPK                                    Mitogen Activated Protein Kinase 
MITF                                      Microphthalmia-Associated Transcription Factor  
α-MEM    α-modified minimal essential medium 
NK                                          Natural Killer  
NZM    New Zealand Melanoma 
OS     Overall survival 
PBS     Phosphate buffered saline 
PD1    Programmed cell death protein 1 
PI3K/AKT                             Phosphoinositide 3-Kinase/AKT  
PIs                                          Phosphoinositides  
Pros 1                                     Protein S  
PTEN    Phosphatase and Tensin homolog 
RTKs                                    Receptor Tyrosine Kinases  
RT-PCR                                 Real Time PCR  
SD     Standard Deviation SDS  
SDS     Sodium dodecyl sulfate 
SHBG    Sex hormone-binding globulin 
STAT1   Signal transducer and activator of transcription 1 
TAM                                      Tyro3, Axl and Mer  
TKs                                         Tyrosine Kinases  
TLR    Toll Like receptor  
VIM    Vimentin 
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1.1 Cancer   
Cancer is the second most cause of death after heart disease worldwide. It is characterized by 
aberrant cell proliferation endangered by multiple genetic modifications and somatic mutations 
in the cells, lead to the tumor formation. A tumor can achieve the ability to invade neighboring 
tissue and spread to healthy distant organs, by a process called metastasis [1, 2]. The inherent 
complexity of cancer makes it difficult to treat and explains why it is as one of the deadliest 
diseases worldwide. In 2012, the number of new cases of cancer diagnosed was 14.1 million 
and it was reported that 8.2 million died from this disease. Of all types of cancer, the most 
common types are epithelial-derived carcinomas of the lung, breast and colon; lung, liver and 
stomach cancers are the three most common causes of cancer related death worldwide [3].  
In Norway, approximately 32827 new cancer cases were reported in 2016, where males 
contributed 54.1 % and females 45.9%. There were 10 944 deaths reported in Norway owing 
to cancer in 2015. Almost 50% of the cancer mortality are caused by the lung, colon, rectum, 
prostate and female breast cancer. The data in 2011 to 2015 from cancer registry in Norway 
showed that the melanoma is the sixth prevalent cancer in male and fourth in female as well as 
the mortality rate is high compared to other types of cancers (see Figure 1 & Figure 2) [4].  
 









Figure 2: Age-standardized (Norwegian standard) mortality rates per 100 000 person-years for selected 
cancers, 2015 Adapted from [4]. 
 
1.2 Tumor heterogeneity 
Cancer is very aggressive and dynamic disease. During progression tumors become 
increasingly heterogeneous. Different clones with distinct characteristics are found in tumors. 
The heterogeneity can be spatial and temporal. The spatial heterogeneity exhibits the variation 
of genetic makeup within and across the cells of a tumor subpopulation; and temporal 
heterogeneity is the alteration in molecular level in the tumor cell [5]. The genetic differences 
that are found within a tumor and between tumors are called intratumoral and intertumoral 
heterogeneity respectively. Tumors from different tissues of one patient and from same tissue 
of two different patients are phenotypically and genetically distant [6]. Moreover, different sub 
clones based on epigenetic and genetic differences are found in the same population of a tumor 
(see Figure 3). The genome of a cancer cell is unstable which leads to increased mutations and 
generation of diverse sub clones in a bulk tumor [7].  
Different cancer types have different recurrent mutations. Colorectal cancer is often caused by 
the mutation in the tumor suppressor gene APC; a form of breast cancer is caused by the gene 
amplification of the HER2 gene [8]; the BRAF(V600E) oncogenic mutation is common in 
melanoma as well as in colon cancer [9], and small cell lung cancer frequently exhibits 
activating EGFR receptor mutations [10]. Subsequent genetic instability and epigenetic 







Figure 3: Tumor heterogeneity. Adapted from [7] 
 
1.3 The prevalence of somatic mutation in cancer 
Most somatic mutations are caused by incomplete DNA repair following errors in the DNA 
replication and base damage by reactive oxygen from metabolic reactions or exposure to 
exogenous mutagens. Several pathogenic viruses (e.g. human papilloma virus, Epstein Barr 
virus) and some bacteria (Helicobacter pylori) are oncogenic. 
 
In lung cancer, somatic mutation can be caused by tobacco smoking; meanwhile ultraviolet 
exposure can cause melanoma [12]. The prevalence of somatic mutations is approximately 
400 per megabase (Mb) in melanoma that is higher than any other classes of cancer, starting 
from about 0.001 per in pilocytic astrocytoma. The fewest mutations are found in childhood 
cancer types compared to malignant melanoma that are caused by high ultraviolet (mutagen) 
exposure (see Figure 4) [6].  
In malignant melanoma, somatic mutations are commonly observed mostly in BRAF, NRAS 
and PTEN genes. Activating mutations in these genes drive cell signaling important for cell 
proliferation and survival. The most frequent mutation in BRAF is substitution of amino acid 
glutamic acid for valine leading the BRAF (V600E) gene mutation that harbors in 50-60% of all 
melanomas. Q61R mutation in NRAS gene is detected in 15% of all type of mutation [13, 14]. Some 
of the malignant melanoma are caused by mutated PTEN, hence the frequency is lot less compared 







Figure 4: The prevalence of somatic mutations among human cancer types: Each dot shows one 
single sample. However, red colored horizontal lines are the median frequency of somatic mutations 
in the various cancer types. The vertical axis (log scaled) represents the frequency of somatic 
mutations per megabase. The horizontal axis represents different cancer type compared on their 
prevalence of somatic mutations from lowest 0.001 per megabase (Mb) in pilocytic astrocytoma to 
highest 400 per Mb in melanoma. Adapted from [6].  
 
1.4 Melanoma 
Melanoma is a type of skin cancer that is highly aggressive and responsible for approximately 
75% of skin cancer related deaths [4]. The prevalence of melanoma is increasing. In males and 
females, melanoma is the 5th and 6th most prevalent cancer, respectively in Norway [16]. Every 
year approximately 132,000 new malignant melanoma cases are identified worldwide, as 
reported by World Health Organization (WHO), which is higher than any other forms of cancer 
[17, 18]. The mortality rate is also increasing with the high incidence rate and particularly in 
the last 10 years. Fair-skinned individuals are more susceptible to melanoma than dark-skinned 
individuals because of the low production of melanin (a pigment found in hair, skin, eyes, and 
some internal membranes) that is present in the cells of the epidermis of the skin. Melanin 
protects against DNA damage (thymidine dimers) by filtering ultraviolet light [19]. Melanin is 
produced by melanocytes, located in the basal layer of skin epidermis and is transferred to 
surrounding cells such as keratinocytes [20]. The malignant transformation of the melanocyte 
causes melanoma. Melanocytes are primarily found in epidermis, some are found in mucous 
membrane, as well as in eyes and in different body parts. Melanomas that arise in the epidermis 
are called the cutaneous melanoma and these account for 90% of all types of melanoma. Others 
include mucosal melanoma from mucous membrane and ocular stroma of the eye termed uveal 









Australia and New Zealand have a higher incidence of melanoma, than western and northern 
Europe. In comparison to other European countries, Norway has one of the highest melanoma 
incidences. Although the incidence rate is lower than of Australia, the mortality rate is similar 
[23]. From the 1950s to date, there has been an alarming increase in the incidence rate of 
melanoma reported in cancer registry of Norway (see Figure 5). 
In the last 60 years, an eight-fold increase in melanoma that is 20% increase in incidence has 
been observed (from 2007-2011 to 2012-2016) in Norway, which makes melanoma the fifth 
most prevalent cancer type, accounting for around 6% of all cancer types. For adults aged 25-
49 in Norway, it is the second most frequent cancer. Around 2000 new cases of melanoma were 
reported in 2015 by the cancer registry of Norway [22, 24]. The melanoma incidence and 
mortality are summarized in Table 1.  
The risk factors for developing melanoma are predominantly genetic and environmental. These 
include exposure to UV radiation, family history of melanoma as well as somatic mutation can 






Figure 5: Trends in incidence and mortality rates and 5-year relative survival proportions in male and 
female melanoma cases from 1995 to 2015 in Norway. Incidence and mortality rates (rates per 100,000) 
correspond to the data on left Y-axis; 5-year survival rates correspond to the data on right Y-axis. 
Adapted from [22]. 
 
 Classification and Staging of Melanoma  
Based on the tumor-node-metastases (TNM) classification system, the AJCC (American Joint 
Committee on Cancer) system of staging melanoma divides patients into several stages of 
disease progression. The TNM system characterizes the tumor based on the size; nature and 
dissemination of tumors. Moreover, the characterization also depends on the evolution of 
primary tumors (T) to their regional lymphatic (N) or distant metastatic (M) spread [27, 28]. 
A schematic representation of four main stages of melanoma that are associated with the 
pathological features is presented in (see Figure 6 ) [29]. 
 
Melanoma-in-situ patients are categorized (clinical and pathological staging) as Tis and 
considered to be in stage 0. Tumors up to 2mm in thickness are considered as primary melanoma 
and do not metastasize regionally or distantly (see Figure 6). The subdivisions of Stage I are 
stage IA without ulceration (T1a) and stage IB that are with ulceration (T1b, T2a) [27, 28]. 
Tumors > 1.01 mm thick without indication of regional lymphatic or distant metastases are 
characterized as Stage II patients (see Figure 6). Stage II is subdivided into Stage IIA, Stage 
IIB and Stage IIC depending on size of the tumor and the presence of ulceration (range from 
T2b, T3a, T3b, T4a and T4b) [27, 28]. If the lesion of a patient spreads regionally and 
metastasize that patients is staged clinically as Stage III (Any T and N1-N3) (see Figure 6). 





size, types of lymph node and the presence of ulceration in primary or metastatic lesions, the 




Figure 6: Stages of melanoma progression. Schematic Comparison between healthy skin and 
malignant melanoma affected skin. During stage 0, the tumor is confined to epidermis and in stage I it 
penetrates epidermis followed by stage II where the tumors spread into the dermis of the skin. At Stage 
III, the subcutaneous layer is penetrated by the tumor and it metastasizes to the lymph node. By Stage 
IV, tumors have metastasized to distant organs. Adapted from [29] 
 
Stage IV patients (clinical and pathological staging) are metastasized to distant organ (Figure 
6) locations such as skin, lung, lymph nodes, subcutaneous tissue, or other visceral or distant 
sites followed by elevated serum levels of lactate dehydrogenase (LDH). The metastasis 
happens very early, from tiny lesions leads to poor prognosis of the patient. The expected 







 Treatment of metastatic and inoperable melanoma 
The past 7 years, the treatment of advanced stage melanoma has changed dramatically. Until 
2011, the standard of care with the chemotherapeutic dacarbazine remained unchanged for over 
30 years, even though it did not improve the overall survival of patients [31]. The US Food and 
Drug Administration (FDA) approvals of the immunotherapeutic checkpoint inhibitor 
Ipilimumab and the targeted BRAF inhibitor Vemurafenib in 2011 for the treatment of 
metastatic or inoperable melanoma marked the beginning for a new era in the treatment of 
advanced melanoma [32]. 
Treatment with immune checkpoint inhibitors improves overall survival, and for both the 
CTLA-4 targeting checkpoint inhibitor Ipilimumab, and PD-1 targeting checkpoint inhibitors, 
unprecedented long- lasting responses are seen [33]. However, the majority of patients either 
do not respond to this treatment, or relapse [34]. 
The BRAF inhibitor Vemurafenib also improves overall survival in patients with BRAF 
mutated melanoma [35], but development of resistance is almost inevitable  [32]. To improve 
the survival competing with incidence, new diagnostic techniques and different therapeutic 
methods are being launched as better options. However, advanced stage melanoma patients 
have lower survival rates and treatment options are still limited. In addition to that, resistance 
to the treatment poses a consistent problem [36-38]. Surgery, chemotherapy, radiation therapy, 
and immunotherapy are currently used to treat melanoma.  The understanding of genetic and 
molecular mechanism of melanoma has improved with increasing research on melanoma. 
Therefore, new drugs are being approved to treat malignant melanoma. Conventional 
chemotherapies like treatment with cytokines (5-20%) effect on advance stage melanoma 
patients. The treatments do not increase survival but rather result in toxicity [35, 39]. Early 
detection and surgical removal of the primary tumor lesion can increase life expectancy of 
patient. Novel treatment options, T-cell regulatory immune therapies like the human anti-
cytotoxic T lymphocyte antigen-4 monoclonal antibodies (ipilimumab) [31], anti-programmed 
death-1 (PD-1) antibodies (pembrolizumab, nivolumab) [40] and targeted therapies against 
MAPK pathway kinases for example BRAF inhibitors, (dabrafenib) [41, 42] show great 
promise and extended survival. Moreover, MEK inhibitor (trametinib) [43] and their 
combination with BRAF inhibitors (dabrafenib with trametinib) [44] showed promising effect 
on melanoma patients with BRAF mutation since several findings show that 50% of melanomas 






Table 2: Treatment of malignant melanoma. The FDA approval is set for different stages of 
melanoma, mainly advanced disease. The NCT: NCT00937937 and BGB324 is an ongoing 





Targeted therapy combinations are showing remarkable progress [47]. In Norway, BGB324 
(AXL kinase inhibitor) drug is in clinical trial to treat metastatic melanoma patients. Depending 
on the BRAF mutation status, the BGB324 can be used as combination therapy with 





inhibitors show promising results [48]. Moreover, wide understanding about other signaling 
pathways and new biomarker invention has led to more new drug discovery that are approved 
by the FDA. The new drug development have driven the research on melanoma to target one 
combination drug therapy with an ambition to overcome drug resistance.  However, the 
acquired resistance negatively influences treatment, which explains why appropriate 
sequencing and selection of drugs still be a challenge. Currently some FDA approved drugs are 
being used to treat melanoma as well as some drugs are in ongoing trial in the hospitals (Table 
2). 
 
1.5 Receptor tyrosine kinases (RTKs)  
Receptor tyrosine kinases (RTKs) are single pass transmembrane receptor proteins expressed 
on the cell surface that transmitting signals from the outside of the cell to coordinate cellular 
processes. Ligands bind to the RTK extracellular domain driving dimerization that results 
autophosphorylation tyrosine residues in the intracellular kinase domain. Phosphotyrosine 
residues trigger activation of different signaling pathways by recruiting signaling 
intermediates (e.g. SH2 protein) that bind distinct tyrosine residues. There are 58 RTKs have 
already been discovered in the human genome, distributed among 20 subfamilies [49-51].  
The structure of all members of RTK superfamily are similar, with a large extracellular 
domain for ligand binding that is connected by a single-chain membrane-spanning 
transmembrane helix to the cytoplasmic tyrosine kinase domain. The activation of RTKs 
typically happened by binding of the ligand to the extracellular domain that induces 
dimerization of the receptor and activation of cytoplasmic kinase domain [51]. In normal 
cells, RTKs are activated after ligand binding. However, in cancer cells, RTKs can be 
overexpressed or they can become constitutively activated by activating mutations [52]. 






Figure 7: Receptor tyrosine kinases (RTKs) families. Adapted from [51]. 
 
 Signaling pathway regulated by receptor tyrosine kinases 
Signaling through RTKs can be mediated through a canonical and a non-canonical pathway. 
The canonical pathways were explained previously, as the binding of the ligand to the 
extracellular domain activates the receptor by dimerization and autophosphorylation of the 
cytoplasmic kinase domain, facilitates binding of downstream effector protein that activates a 
particular signaling cascade into the cell.  On the other hand, the internalization of RTKs 
followed by translocation into the cell surface and nucleus carry the signal from outside of the 
cell to inside, in the non-canonical signaling pathways [53, 54]. The thesis mainly focused on 
canonical pathway proteins. 
There are mainly two main signaling cascade that can be referred as the canonical pathways. 
After binding of ligand to the RTKs, consequently the dimerization and autophosphorylation 
of receptor and kinase domain mediate the recruitment of several adaptor proteins to the 
phosphorylation site. The binding of an adaptor protein can activate the two main downstream 
signaling cascade, the Growth factor receptor-bound protein 2 (Grb-2) adaptor protein activates 
the Ras mediated  mitogen-activated protein kinase (MAP kinase)/ERK pathway, whereas the 
regulatory subunit (p85) of phosphoinositide 3-kinase (PI3K), works as an adapter protein to 





In the MAP kinase/ERK pathway, the Ras is inactive and GDP bound in the absence of a growth 
factor. However, upon binding with the growth factor, the activated adaptor protein Grb-2 
initiates the Ras and a conformational change triggers the exchange of bound guanosine 
diphosphate (GDP) for guanosine triphosphate (GTP). Meanwhile, activated Ras triggers the 
downstream signaling protein RAF by phosphorylation that subsequently activates the MEK 
(MAP kinase kinase), ERK (MAP kinase) proteins in the signaling cascade (see Figure 8). The 
phosphorylated ERK then activates the transcription factor for cell proliferation AP1 and cell 
cycle regulatory proteins cyclin D1 that regulates proliferation, survival and differentiation of 
the cell [55, 56].   
 
 
Figure 8: RTK signaling pathways: EGFR is an RTK which is activated by binding of ligand to the 
receptor that causes dimerization, and subsequent activation of downstream signaling protein by 
activated adaptor protein. In the MAPK pathway, sequential activation of RAS, RAF, MEK, and ERK 
by phosphorylation of kinase domain. However, upon activation with p85, the p110 then initiate the 
conversion of PIP3 from PIP2, that trigger the AKT (facilitated by PDPK1 and PDPK2 (mtorC2). The 






In the PI3K/AKT pathway, the regulatory subunit, p85 of PI3K act as an adaptor protein which 
binds to the phosphorylated tyrosine domain of activated receptor. The catalytic subunit, p110 
of PI3K works as a downstream signal mediator to transmit the signal to protein kinase C 
(PKC). PKC mediates the formation of Phosphatidylinositol (3, 4, 5)-trisphosphate (PIP3) from 
Phosphatidylinositol 4, 5-bisphosphate (PIP2) that serves as docking site for Phosphoinositide-
dependent kinase-1 (PDK 1) as well as phosphorylated AKT (also known as protein kinase B) 
[57, 58]. The phosphorylated AKT in turn activates mTOR (a serine threonine kinase) that 
triggers further cell proliferation and cell survival. On the other hand, AKT also phosphorylates 
Bcl-2-associated death promoter (BAD) protein, which induces apoptosis in the cell by binding 
to Bcl-2 in its unphosphorylated state. However, upon phosphorylation by AKT, the pro 
apoptotic function of BAD is inhibited thereby promoting more cell survival. Phosphatase and 
Tensin homolog (PTEN) protein downregulates the PI3K/AKT pathway by forming PIP2 from 
PIP3 [60, 61].  
 
 Tyro3, Axl, Mer is the TAM Receptor tyrosine kinases 
The TAM family consists of three receptors, tyrosine kinase receptor 3 (Tyro3), Axl, and Mer. 
All three TAM receptors consist of three domains, the single pass transmembrane domain is α-
helical that connects the extracellular adhesion molecule-like domain to the intracellular 
tyrosine kinase domain which contains a conserved sequence, (KW(I/L)A(I/L)ES). The 
extracellular domain comprises two immunoglobulin-like (Ig) domains and two fibronectin-
type III (FNIII) domains. The receptor forms dimer upon activation by its ligand and these 
receptors share two types of ligand. First, the growth arrest-specific protein 6 (Gas6) is a 
vitamin K dependent ligand that can bind to all the three TAM receptors. However, the second 
one is vitamin K dependent protein, protein S (PROS1) that can only bind to Tyro3 and Mer 






Figure 9: Activation of TAM receptor by ligand Gas6 & protein S. 
 
The ligand acts as bridging factor by vitamin K-dependent γ-carboxylation of glutamic acid 
residue of the N terminal Gla domain that binds to the phosphatidylserine (PtdSer) and the 
carboxy-terminal domain bind to the receptor [64]. 
In normal cellular function, the phosphatidylserine (PtdSer) is located to the inner leaflet of the 
plasma membrane. Cells that are stressed or apoptotic display phosphatidylserine (PtdSer) on 
the outer leaflet, which will then bind to the ligand Gas6 and protein S [65]. TAM receptors 
mediate clearance of apoptotic cells, innate immune control, and differentiation of natural killer 
cells (NK cells) as well as platelet aggregation [62, 66]. TAM receptors also associated with 
different types of cancer. Aberrant activation of these receptors promotes tumor cell survival, 
chemoresistance and invasion [63]. Axl plays an important role in the tumor metastasis and 
acquired resistance to both conventional cytotoxic drugs, radiation and targeted therapeutics 
and more recently to immune checkpoint inhibitors. Axl is an important drug target to prevent 





 TAM family member, Axl receptor tyrosine kinase 
Axl is one of the members of the TAM family receptor kinase. It was first identified as a 
transforming gene with unknown protein function in two patients with chronic myelogenous 
leukemia (CML) in 1988 [68]. The name Axl comes from Greek “anexeleto” that means 
uncontrolled. The AXL gene is highly conserved in vertebrates, located at close vicinity to the 
BCL3 oncogene in chromosome 19 (19q13.1-q13.2), which are encoded by 20 exons, and have 
two different splice variants [69]. The Axl receptor activation depends on binding of the ligand 
growth-arrest-specific gene 6 (Gas6) in a vitamin K dependent manner. The glycosylated receptor 
is 140kda [68, 70].  Axl is expressed at low levels in myeloid cells, bone marrow stromal 
osteoblasts, platelets, endothelial cells, and specific cells in skeletal muscle, heart, liver, kidney, 
testis, hippocampus and cerebellum. Axl activation induces cell survival, migration, cell- cell 
adhesion and proliferation. [62, 71]. In normal physiological condition, Axl induces cell survival; 
give stimulation to cell to migrate, cell-cell adhesion and proliferation [72, 73]. However, it has 
been reported that Axl overexpression is associated with metastasis, invasion, migration and 
angiogenesis of numerous cancer types like triple negative breast cancer, colon cancer, non-
small-cell lung cancer, prostate cancer, pancreatic cancer, ovarian cancer endometrial cancer 
and sarcomas [74]. 
 
 Structure of Axl 
Since Axl is a receptor tyrosine kinase (RTKs), the structure is like other RTKs. Like other 
RTKs, Axl receptor is characterized by extracellular (N-terminal) ligand binding domain, 
consisting of two-fibronectin type III like repeats, and two immunoglobulin (IG)-like domains 
along with intracellular tyrosine kinase (C-terminal) that encompasses an unusual conserved 
sequence amino acid sequence, (KW (I/L)A(I/L)ES), like other TAM family receptor (see 
Figure 10) [69, 75]. The intracellular kinase domain contains an ATP-binding site that includes 
three autophosphorylation sites (Tyr779, Tyr821, and Tyr866), that can serve as a docking sites for 
numerous intracellular signaling proteins with s binding sites for phosphorylated tyrosine (src-
homology domain-2). Tyr779 exhibits the binding site for PI3K, Tyr866 for PLC and Tyr821 







Figure 10: The schematic representation of structure of Axl receptor and its ligand growth-arrest-
specific gene 6 (Gas6). Adapted from [75] 
 
  Axl activation and signaling 
Axl can be activated by two different mechanisms, depending on ligand availability. The most 
powerful way of activation is ligand dependent activation where the ligand Gas6 binds to the 
extracellular ligand-binding domain of the Axl receptor and activates it. Apart from the ligand-
mediated activation, Axl is reported to activate by homodimerization, which is a ligand 
independent mechanism.  By binding to another Axl receptor, either on a neighboring cell or 
on the same cell, Axl activation has also been shown to occur. In addition, Axl can also be 
activated by binding with other TAM receptors, as well as with non-TAM receptors 






Figure 11: Axl Activation and signaling: A. Three pathways of Axl signaling including (1) 
Ras/Raf/MEK/ERK, (2) Elmo1/2/DOCK1/Rac1/Pak, and (3) Gab2/PI3K/Akt, that can lead to cell 
proliferation, migration and survival. B–F. Mechanisms of Axl activation, including binding of ligand 
Gas6 with the receptor in a ligand-dependent manner (B) homodimeric interaction of Axl with 
neighboring cells (C), as well as overexpression (D), dimerization with another TAM family member 
receptor (Tyro3) (E), or heterodimerization with a non-TAM family receptor, such as EGFR (F) in a 
ligand independent mechanism (C-F). Adapted from [78] 
 
The Axl ligand Gas6 is a 75-kDA vitamin K dependent protein. The amino acid sequence of 
Gas6 is 43% identical to the other ligand for TAM family, protein S. Gas6 is a 75-kDa vitamin 
K dependent protein first identified in fibroblasts of embryonic mouse NIH 3T3 in 1995, as a 
ligand for Axl. The N terminal of the Gas6 protein comprises the gamma-glutamic acid (Gla) 
domain, followed by four epidermal growth factor-like repeats. The C-terminal regions of Gas6 
contains steroid hormone-binding globulin (SHBG) that includes two laminin tandem globular 
(G) domain (see Figure 11) [79-83].  
Each of the Axl receptor molecules contain two sites that have different affinity for distinct 
ligands, one is high affinity site for ligand binding, Ig1 and other is low affinity site for ligand 





complex. The high affinity site, Ig1 of one Axl molecule binds to one side of the Gas6, whereas 
the low affinity site, Ig2 of other Axl molecule binds the opposite side of the same Gas6 and 
causes dimerization of the receptor (see Figure 12) [84]. However, the Gas6 activation depends 
on the gamma carboxylation of the Gla domain, which in normal condition converts glutamate 
to gamma-carboxyglutamate by carboxylation. Upon carboxylation of the Gas6 Gla domain, its 
binding to phosphatidylserine (PtdSer) is facilitated in a calcium dependent manner on the 
neighboring cells [79]. Phosphatidylserine is mainly found in the inner leaflet of the plasma 
membrane that can flipped on the outer surface of the membrane upon activation. Moreover, 
the platelets and dendritic cells as well as ACs also present PtdSer on the outer surface of the 
membrane [85]. 
  
Figure 12: Axl Gas 1:1 complex: Molecular mechanism of binding of Axl to Gas6 by the Ig1 and Ig2 
domains of Axl (green) and the C-terminal laminin G-like domains of Gas6 (blue). The left diagram is 
showing from front and the right one from top. Axl attachment to the membrane are shown using green 
arrow. 
 
There are several conflicting reports suggest, activation of Axl by Gas6 is dependent or 
independent of the phosphatidylserine interaction [63]. This was supported by another study 
that demonstrated that gamma-carboxylation of Gla domain is sufficient for activating the Gas6; 
there is no need of PtdSer for the signaling of the receptor [64]. On the contrary, one group 
suggests that the signaling of Axl  by the activation of the Gla domain of Gas6 without PtdSer 
is weaker (see Figure 13) [86]. However, the most common activation of the Axl receptor is 
carboxylation of the Gla domain, followed by ligand binding of Gas6 to PtdSer [79]. Recent 








Figure 13: Gas6-PtdSer Interaction for Axl signaling: For increased signal, the Gas6-PtdSer 
interaction is necessary. PtdSer aggregates the receptor for more extended signal. 
 
The activation of Axl, either with the vitamin K dependent gamma carboxylation of ligand Gas6 
and PtdSer or through the ligand independent manner, as a tyrosine kinase receptor, results in 
dimerization of Axl that transduces a signal from the outside to the inside of the cell. The signal 
autophosphorylates the tyrosine residues of the C-terminal intracellular kinase domain of Axl 
receptor at the position Tyr779, Tyr821, and Tyr866 [76, 87]. The phosphorylated tyrosines act as 
docking sites for several downstream signaling cascade. For Axl, the main activated downstream 
signaling pathway is PI3K mediated activation of Akt and phosphorylation of nuclear factor κB 
(NF-κB). The regulatory subunit (P85) of PI3K binds to the phosphorylated Tyr866 docking site 
on Axl that subsequently phosphorylates Akt and NF-κB. After phosphorylation, the AKT 
phosphorylates the Bcl-2-associated death promoter (BAD) that blocks the binding of BAD to 
anti apoptotic protein, reducing apoptosis followed by escalated cell survival [88, 89]. However, 
PI3K can phosphorylate NF-κB that inhibits the expression of proapoptotic protein caspase 3 
and exhibits the formation of two major anti apoptotic protein, B-cell lymphoma-extra large 
(Bcl-xL) and Bcl-2 (B-cell lymphoma 2) which in turn promotes more cell survival [62]. PI3K 
can also activate p21 (RAC1) activated kinase 1(PAK1) that leads to increased cell invasion 
[90]. Heat-shock protein 25 is another downstream signaling protein that is activated by PI3K. 
Upon activation, this protein stimulates increased cell migration by actin remodeling [91]. As 
a whole, activation of PI3K signaling pathway by Axl can mediate increased cell proliferation, 
survival, cell motility and migration (see Figure 14) [92, 93]. 
Another pathway that is activated by phosphorylation of Axl is MAPK/ERK pathway. In this 





Ras that will mediate the phosphorylation of Raf1, followed by Mek1 and Erk1, which will increase 
cell proliferation [93]. Axl also inhibit the inflammatory response against pathogens in the innate 
immune system by suppressing the cytokine signaling with Socs1 and Socs3 (suppressor of cytokine 
signaling 1 and 3) that are activated by the phosphorylation of transcription factor Stat1, followed 
by inhibition of toll like receptor (TLR), expressed on the sentinel cells such as dendritic cells and 
macrophages [87, 94]. Axl activation is also related to phosphorylation of the transcription factor 
Stat3 that is overexpressed in several cancers [95]. Axl also regulates the function of endothelial 
cell by modulating the angiopoietin/Tie2 and Dickkopf-homologue 3 (DKK3) signaling pathway. 
The inhibition of angiopoietin/Tie2 and expression of Dickkopf-homologue 3 (DKK3) promotes 
angiogenesis in the tumor cell [96].  
 
 
Figure 14: Downstream signaling cascade of Axl after binding with ligand Gas6. Different signaling 
pathways are activated by Axl that leads to increased cell proliferation, survival, migration, and invasion 







  Axl, plasticity and stemness  
Stem cells have the ability to self-renew and differentiate into mature cell types. Similarly, 
cancer stem cell (CSCs) are neoplastic cells with ability to change phenotype, leading to cancer 
growth, spread and resistance to targeted therapy [97]. In embryonic development, various 
transcription factors regulate signaling of PI3K/Akt/mTOR, Hedgehog (HH), JAK/STAT, 
Wnt/β-catenin and Notch pathways control proliferation, differentiation, self-renewal of stem 
cells. Other transcription factors Twist1, Twist2, Slug, Snail, Zeb1, Zeb2 are characteristic of 
with epithelial mesenchymal transition (EMT) [97, 98]. Axl is upregulated by the EMT 
transcription factors that also modulate posttranscriptional and posttranslational modification 
in the cells that activates N-cadherin and represses E-cadherin [99]. The intermediate filament 
vimentin, a canonical mesenchymal marker, alters cell morphology and increases the migration 
capacity of cancer cells [100]. The correlation between Axl expression with the EMT and 
stemness markers is found in several malignancies, including breast cancer, leukemia, small 
cell lung cancer, prostate carcinoma, ovarian cancer, gastric carcinoma, chronic myeloid 
leukemia (CML), and colorectal cancer [101-104].  
The expression of Axl is higher in the primary tumor as well as in the metastatic tumor 
compared to normal cell. Axl overexpression has correlation with increased invasiveness of the 
tumor cells, development of resistance to drug followed by poor prognosis of patient with 
different cancer. The invasiveness and metastatic properties of cancer cell in lung 
adenocarcinoma and glioblastoma can be increased by the overexpression of Axl via PI3K/AKT 
mediated NF-kB pathway [105, 106]. There is an association between cell proliferation by 
inhibition of apoptosis and Axl overexpression in osteosarcoma, astrocytoma, and ocular 
melanoma [107, 108]. Overexpression of Axl also has a correlation with the angiogenesis in 
cancer (new blood vessel formation) [109]. 
 
 Axl in cancer 
It has been shown in different studies that overexpression of Axl mediated PI3K/AKT signaling 
enhance the NF-kB pathway and has a correlation with the increased tumor cell invasion in the 
ovarian, breast, gastric cancer. Downregulation of this signaling leads to the decreased invasive 
properties of the cells in hepatic carcinoma [110-112]. The activation of Pak1 by Axl mediated 
PI3K/AKT signaling triggers cell invasion and inhibition of Axl reduces the PAK1 activation 





inhibit NK cell to trigger Casitas B lineage lymphoma b metastasis. The inhibition of Axl can 
downregulate the metastasis of Casitas B lineage lymphoma b [113]. In other different cancer 
types, Axl overexpression leads to prolonged cell survival. PI3K/AKT signaling activated by 
Axl receptor inhibits the pro apoptotic BAD protein by phosphorylation and activates the Bcl-
2 and Bcl-XL anti apoptotic protein to reduce apoptosis found in breast cancer, osteosarcoma, 
ocular melanoma and chronic lymphatic leukemia [107, 108, 114]. Axl has role in the VEGF 
dependent PI3K/AKT activation that promotes vascular angiogenesis. It has been suggested 
that knockdown of Axl leads to impaired tube formation in endothelial cells and suppresses 
new blood vessel formation [115]. The tumor microenvironment is also regulated by Axl. 
Compared to normal tissue, the microenvironment of tumor produces more HIF1α in the 
hypoxic condition that enhance the transcription of Axl [116]. Axl also increases the expression 
of MMP-9 (Matrix metallopeptidase 9) that helps cancer cells to degrade the collagen type IV 
of the basement membrane to penetrate the blood vessel and travel to distant organ for further 
metastasis [117].  
 
 Axl in drug resistance 
Axl expression is not only associated with cell proliferation, survival, migration, and metastasis 
but it is also tightly linked to the development of therapeutic resistance. The malignant 
melanoma patient carrying B-Raf proto-oncogene serine/threonine kinase (BRAF) mutation 
treated with BRAF-inhibitors have been found resistant to the inhibitor (see Figure 15) [36]. 
The Axl dimerize with other RTKs to give therapeutic resistance, such as in lung cancer it forms 
dimer with EGFR to give downstream signal. Thus, Axl supports cancer cells to achieve 
therapeutic resistance in different cancers [118].  Several studies show overexpression of Axl 
in different therapy resistant cancers. However, the mechanism is still unclear [119]. In lung 
cancer treatment, the anti EGFR therapy, cetuximab showed promising effect. Nevertheless, 
overexpression and dimerization of Axl to the EGFR receptor reduce the treatment effect with 
anti EGFR therapy, by activating the downstream signaling [118]. There are other studies 
suggesting that the overexpression of Axl have effect on therapy resistance in breast cancer 






Figure 15: Patient with BRAF-inhibitor. A 38-year-old man with BRAF mutant melanoma. Pictures 
were taken (A) before treatment with PLX4032, (B) after 15 weeks of treatment with PLX4032, and (C) 
after 23 weeks of treatment, recurrence of melanoma. Adapted from [36]. 
 
1.6 Vitamin K, a cofactor for γ-glutamyl carboxylase (GGCX) to activate Gas6 
A Danish scientist Henrik Dam first discovered vitamin K in the 1930s. Several vitamin K 
dependent protein (VKDPs) is activated by the γ-carboxylation of the glutamic acid residue in 
the body. Vitamin K serves as the cofactor for the enzyme γ-glutamyl carboxylase (GGCX) that 
catalyzes the γ-carboxylation of the glutamic acid residues. Vitamin K dependent proteins that 
are activated by γ-carboxylation are participated in several important biological functions such 
as signal transduction, vascular calcification, bone metabolism, cell proliferation, and mostly 
in blood coagulation [120]. Enzyme gamma-glutamyl carboxylase (GGCX) utilizes one 
molecule of reduced vitamin K hydroquinone (reduced form of vitamin K or KH2- active form), 
oxygen and carbon dioxide as cofactors and produce one molecule of oxidized vitamin K 2,3-
epoxide (KO- inactive form). Simultaneously with the reaction, each glutamate on the vitamin 
K dependent protein is transformed to γ-carboxyglutamate by incorporation of additional 
carbon dioxide to the γ- carbon [121]. For reutilizing the vitamin K 2,3-epoxide, it is reduced 
back to vitamin k by the enzyme vitamin K epoxide reductase (VKOR) and further reduced to 
vitamin K hydroquinone by the enzyme vitamin K reductase (VKR). The enzymes in the 






Figure 16: Vitamin K Cycle. Adapted from [121] 
 
1.7 Warfarin is cancer reductionist 
The most used anticoagulant drug in worldwide is warfarin. Around 2-10% adult population 
use this orally administered anticoagulant. After the administration, the body completely absorb 
the warfarin. The 98-99% of warfarin bound to the albumin (plasma protein) in the body. The 
liver mostly CYP2C9 metabolizes the warfarin completely after plasma concentration of it gets 
highest level after 4 hours [123, 124]. Warfarin works as the antagonist of vitamin K. It blocks 
the enzyme vitamin K epoxide reductase (VKOR) to convert vitamin K hydroquinone from 
vitamin K epoxide. As inactivation of the vitamin K cycle, the vitamin K concentration reduces 
in the body [125]. In the absence of vitamin K, the Gla carboxylation of the vitamin K dependent 
proteins will reduced. The ligand Gas6 is a vitamin K dependent protein and without vitamin k 
Gas6 can bind to the receptor Axl, hence cannot activate the receptor. The Axl is inhibited by 
the warfarin treatment is mentioned in the article by Gry Haaland named, "Association of 






1.8 Axl, a regulator of melanoma progression as chemotherapeutic resistance 
Researchers are trying to understand the importance of Axl in development of melanoma, their 
effect in metastasis and association with drug resistance. Since 50% of the melanoma is caused 
by BRAF mutation and Raf signals downstream of the MAPK pathway. However, cancer cells 
somehow acquire resistance against BRAF inhibitors, which means they are bypassing the 
signaling cascade. It is also found that, combination therapy with BRAF inhibitor and Axl 
inhibitor exhibits better effect suggesting that Axl is the alternative pathway that allows play a 
role in acquired resistance [127].  Some other researchers showed that increased cell invasion 
and migration followed by metastasis of melanoma linked with upregulation of Axl. Knocking 
down Axl or use of the inhibitor R428 (also known as BGB324 or Bemcentinib) against Axl 
improves disease by declining invasion and migration but less of an effect on cell proliferation 
[128, 129]. MITF (microphthalmia‐associated transcription factor) a transcription factor that 
has been linked with Axl to provide acquired resistance against therapies. It is found that MITF 
has some effect in suppression of melanoma and inhibition of metastatic phenotype [130]. 
 
1.9 Axl and vitamin K 
As previously described, Axl receptor tyrosine kinase is activated by the vitamin K dependent 
ligand Gas6. Upon γ-carboxylation of the Gla domain of the ligand Gas6 by vitamin K 
dependent enzyme GGCX, Gas6 can activate Axl. The non-carboxylated gas6 can bind to the 
Axl, but is unable to activate Axl and therefore the downstream signal but some reports claim 
it can mediate limited signal [131]. To date, link between vitamin K pathways with the 
therapeutic resistance of melanoma is still unclear and unexplored. The mechanism behind 







2 Aims of the study 
The aim of this thesis is to understand if the Axl mediated signaling has any effect in cancer 
progression, metastasis and therapy resistance in a series of melanoma cell lines established at 
the Auckland Cancer Society Research Centre (ACSRC).  
The specific aims of the study are: 
• Characterize the expression of Axl, Gas 6 and vitamin K enzymes in a panel of 21  
melanoma cell lines 
• Determine whether expression of Axl, Gas6 and vitamin K enzymes are correlated  with 
poor prognosis of melanoma patients  
• Characterize the effect of vitamin K on cell migration, proliferation and spheroid 
formation in melanoma cell lines 
• Measure the effect of the vitamin K and Axl inhibitor BGB324 on the expression of 
plasticity markers and other relevant genes in the melanoma cell lines.  
• Apply the findings from these aims to study pathways involved in drug resistance and 






3 Materials & Methods 
3.1 Cell culture  
 Cell Lines 
The twenty New Zealand melanoma (NZM) cell lines used for this study were obtained from 
surgical samples of metastatic melanoma from Professor Bruce Baguley’s laboratory, the 
University of Auckland, New Zealand, and the CRISPR Axl knockout of NZM 17 line was 
obtained from Jing Kang, PhD candidate at the University of Bergen (see Table 3). Written 
consent was obtained from all patients under Auckland Area Health Board Ethics Committee 
guidelines.  
Table 3: Cell line panel. Patient cell line with BRAF mutation status and the treatments they have 
received. Adopted from [132]  
Cell line BRAF V600E mutation Patient Therapy 
NZM 1 Absent Surgery and Radiotherapy 
NZM 2 Absent Surgery and Radiotherapy 
NZM 3 Present Surgery and Radiotherapy 
NZM 4 Present POC chemotherapy, 2 cycles 
Commenced after tissue collection 
NZM 6 Present Surgery and Radiotherapy 
NZM 7 Present Surgery and Radiotherapy 
NZM 9 Absent Surgery and Radiotherapy 
NZM 11 Present POC chemotherapy, 6 cycles 
Treatment commenced after tissue 
collection 
NZM 17WT Absent Received vaccination before tissue 
collection 
NZM 17AXL-/- Absent  
NZM 20 Present Surgery and Radiotherapy 
NZM 30 Present Surgery and Radiotherapy 
NZM 34 Present Received vaccination after tissue collection 





Received before tissue collection DMXAA 
IFN, Received vaccine 
Commenced after tissue collection 
NZM 46 Absent No information 
NZM 55 Present Temozolomide – one cycle. Received after 
tissue collection – July, 2005.  
Tissue collected: 10.11.2004 
NZM 61 Absent Surgery and Radiotherapy 
NZM 63 Absent DTIC chemotherapy 
4 cycles 
Commenced after tissue collection 
NZM 76 Present No information 
NZM 86 Absent Surgery and Radiotherapy 
NZM 100 Present Surgery and Radiotherapy 
 
 General maintenance of NZM cell lines 
NZM cell lines were cultured in α-modified minimal essential medium supplemented with 
insulin (5 μg/ml), transferring (5 μg/ml), and sodium selenite (5ng/ml), 100 U/ml of penicillin, 
100 μg/ml of streptomycin (PS), 5% fetal bovine serum (FBS). The cell lines were cultured in 
a humidified low oxygen incubator (5% O2, 5% CO2, 37 °C) to maintain physiologically oxygen 
levels instead of conventional incubators with atmospheric level (21% O2). 
The cell lines were handled in a clean lamina flow hood to maintain sterility and were checked 
daily under a Nikon ECLIPSE TS100 microscope to monitor confluence. The cells were 
cultured in 75 cm2 (T75) flasks and split in 10 cm petri dishes for RNA and protein extraction. 
Images of cells were captured occasionally on a Nikon D3000 microscope to monitor changes 






 Cell thawing procedure 
Cell culture medium was warmed in a 37°C water bath for 30 minutes before thawing cells 
from liquid N2 storage. The cryovials that contain approximately one million cells of each NZM 
cell line were taken out from liquid nitrogen storage and were instantly placed into the 37°C 
water bath. The vials were transferred into the lamina flow hood after thawing. Before being 
put into the hood, the vials were wiped with 70% ethanol to avoid contamination. The cells in 
each vial were transferred to a 25 cm2 (T25) flasks using 5 ml of media and the flasks were then 
put into a low oxygen incubator (5% O2, 5% CO2, 37 °C). The medium was exchanged with 
fresh medium the next day. After the cells reached 80% confluency, they were transferred into 
75 cm2 (T75) flasks for further growth. 
 
3.1.4 Cell passaging procedure  
After the cells reached a confluency of approximately 70-90% they were passaged, every 2-3 
days. However, since each of the cell lines have different growth rates, some needed to be 
passaged more frequently to prevent overgrowth, while other cells only received fresh medium. 
Cell culture medium, trypsin-EDTA and PBS were pre-warmed for approximately 30 minutes 
in a 37°C water bath before passaging. First, medium was collected (for reseeding the non-
adherent cells) and centrifuged, cells were washed with 5 ml 1×PBS, then 3 ml trypsin-EDTA 
was added to each 75 cm2 (T75) flask. Flasks were placed into incubator for 2-3 minutes, the 
trypsinized cells were observed under a light microscope. To hasten the process of detachment, 
the side of the flask was agitated gently several times until the cells were completely detached. 
To stop trypsin activity, 3 ml of fresh serum containing medium was added and the cell 
suspension was transferred to 15 ml tubes and was centrifuged at 1200 rpm for 5 minutes. Then 
the centrifuged cells were resuspended with fresh media after the supernatant was removed. 
The resuspended cells were transferred into a new dish or flask. Each of the cell line’s RNA 
and protein were extracted from three passages. For each cell line, one 75 cm2 (T75) flask was 
split into two 10 cm plates (one for RNA and another for protein extraction) and one 75 cm2 
(T75) flask (for next passage). Cells were also seeded in T75 flasks for future CyTOF analysis 






 Cell freezing  
Continuous culturing of cell lines can make them more prone to genetic drift, microbial 
contamination, senescence and equipment failure can cause destruction of the cell lines [133]. 
It is therefore important to freeze the cells in liquid nitrogen for long-term storage. After 
reaching 70-90% confluency, the cells were washed with PBS, trypsinized (as previously 
described in 1.1.4) and centrifuged at 1200 rpm for 5 minutes. After centrifugation, the cells 
were resuspended in freezing medium (20% FBS and 10% DMSO in α-modified minimal 
essential medium). Cell density of 1×106 cells per ml was prepared and 1 ml was transferred 
into each cryovial. The vials were labeled with cell line names, passage number and date, 
transferred into a freezer box containing isopropanol, and put into -80°C overnight before 
transferring into liquid nitrogen for long-term storage. 
 
 Cell counting and quantifying viability  
Counting of the cells was normally performed using the Countess automated cell counter from 
Invitrogen. If the cells had a low concentration, the counting was performed using a 
hemocytometer. The Countess contains a slide port where cell counting chamber slides can be 
inserted. 10 µl of cells suspended in media was mixed with 10 µl of trypan blue (If cells take 
up trypan blue, they are considered non-viable) [134]. 10 µl of the sample mixture was 
transferred to the chamber port on one side of the Countess Cell Counting chamber slide, which 
was then inserted into the instrument. Upon activation, the machine counted the live and dead 
cells indicating the viability percentage. 
 
3.2 Gene expression analysis by RT-PCR  
 Cell preparation for RNA extraction  
When reaching 70- 90% confluency on a 10 cm plate, cells where scraped were scraped in PBS, 
transferred to a 15ml tube and centrifuged at 1200 rpm for 5 minutes.  The PBS was aspirated 
and the cells were resuspended in 1ml cold PBS, transferred to 1.5 ml Eppendorf tube, 
centrifuged at 1200 rpm for 5 minutes. The PBS was aspirated and the pelleted cells were 






 RNeasy Mini Kit (50) for RNA extraction 
RNA was extracted using the RNEasy Mini Kit from Qiagen following the manufacturer’s 
instructions. Cell pellets were removed from -80 freezer and gently thawed by flicking. The 
RNA can be degraded by vortexing, so this was avoided. After properly thawing, 600 μl buffer 
RLT was added in the Eppendorf tube to disrupt the cell pellet, and to lyse the cells. For proper 
homogenization of the cells, a motor cordless homogenizer was used. Each sample was 
homogenized for 25-30 sec depending on the cell pellets.  Equal amount (600 μl) of 70% ethanol 
was added to the lysate and mixed thoroughly by pipetting. The lysate was transferred to a 
RNEasy spin column with 2 ml collection tubes and centrifuged at 10,000 rpm for 15s. The 
flow through was discarded The membrane spin column now containing bound RNA was 
washed with 700 μl buffer RW1 and centrifuging at 10,000 rpm for 15s. Buffer RW1 contain 
guanidine salt that washed away carbohydrate, fatty acid and protein. The flow-through was 
discarded and 500 μl of RPE buffer was added to the spin column to remove salts from the 
membrane and in the same manner, centrifuged at 10,000 rpm for 15s. The flow-through was 
discarded, 500 μl buffer RPE was added for the second wash and centrifuged at 10,000 rpm for 
2 minutes. The collection tube with flow through was replaced and samples were centrifuged 
for 1 minute at maximum speed to collect the residual flow through. Consequently, the 
collection tube was replaced with a new 1.5 ml Eppendorf tube.  Finally, 30 μl of RNase-free 
water was added to the column and centrifuged at 10,000 rpm for 1 min to elute the RNA. RNA 
concentration was measured with NanoDrop by reading absorbance at 260nm.  
 
 Re-precipitating RNA 
The concentration and purity of extracted RNA can be affected by chemical contamination. 
Chemically contaminated RNA was re-precipitated in 10% volume of sodium acetate (3M, pH 
5.2) and 2X volume of 100% ethanol and incubated overnight at -20 °C. Samples were 
centrifuged the next day for 40 minutes at 18,000 rpm at 4°C. The supernatant was discarded 
and the RNA pellet was resuspended by gently flicking in RNase free water containing 70% 
ethanol. After resuspension, the tubes were centrifuged at 18,000 rpm for 15 minutes at 4°C. 
The supernatant was decanted and the pellet resuspended in 100% ethanol and centrifuged at 
18,000 rpm for 40 minutes at 4°C. Accordingly, the supernatant was discarded and the pellet 
were resuspended in 27 μl RNase-free water and incubated at room temperature for 10 minutes. 





acid is maximum at 280 nm and minimum at 260nm. A 260/280 ratio of ~2.0 indicates that the 
extracted RNA is pure.  
 
 Synthesis of cDNA 
cDNA was made with 4000 ng of RNA using High Capacity cDNA Reverse Transcription Kit 
in a 20 μl reaction. The master mix was made combining 4μl 10X RT buffer, 4 μl 10X RT 
random primers , 1.6 μl 25X dNTP Mix 100mM, 2μl reverse transcriptase and 8.4 μl water. The 
20 μl sample and 20 μl of master mix were then added together and mixed properly to make it 
40 μl. The mixture was transferred in the thermal cycler with the loading program 10 min at 
25ºC, 120 min at 37ºC, 5 min at 85ºC and, samples were held at 4ºC (see Table 4). After making 
cDNA, equal volume (40 μl) of nuclease free water was added to avoid DNA degradation. The 
cDNAs were then ready for use in RT-PCR and the rest were stored at -20ºC (see Table 4). 
 
Table 4:  cDNA synthesis reagents and equipment. 
cDNA Synthesis 
Material Supplier 
High-Capacity cDNA Reverse Transcription Kit Applied Biosystems 
Ambion® Nuclease-Free Water Roche 
Thermal cycler BIO-RAD 
 
 Quantitative PCR (qPCR) 
For gene expression analysis, probe based quantitative PCR (qPCR) also known as real time 
polymerase chain reaction (RT-PCR) was used. It is a powerful and sensitive tool for detecting 
specific mRNA quantity in samples of interest. The qPCR machine named LightCycler® 480 
system (Roche) measures the intensity of the florescence emitted by the probe at each cycle of 
the reaction. After first cycle, the florescence intensity is not enough to detect. However, as the 
reaction advances, new amplicons are generated that will increase the florescence intensity as 
well as background intensity. The LightCycler software determines a threshold level to reduce 





Ct (threshold cycle) values that represents the number of cycle needed to detect the real 
florescence intensity from the sample [135].  
After the synthesis of cDNA from different RNA samples, 30 µl reaction mix for each sample 
was made and transferred in a 384 well plate. Each of the 30 µl reaction mix contained 15 µl 
LightCycler® 480 Roche master mix, 1.5 µl TaqMan probe of interest, 9 µl RNase free water, 
4.5 µl cDNA of interest. In a 384 well plate, each well contained 10 µl of reaction mix (see 
Table 6). For each sample, three technical replicates were used. For normalizing the 
experimental error in qPCR, two normalization technique can be used. One is the normalization 
to total RNA that needs reliable method for total RNA quantification and other is using 
housekeeping gene that is more expected method [136]  GAPDH was used as it is most 
commonly used housekeeping gene. Other housekeeping genes including, PPIA, 18s rRNA, β-
ACTIN (ACTB) and Tata Binding Protein (TBP), can be used depending on different 
experiment conditions for normalization. The 384 well plate with the sample and housekeeping 
gene was then loaded to the LightCycler® 480 system for running with the following setting as 
listed in (see Table 5) 
 
Table 5: Light Cycle 480 system program settings. 
PCR Stages Temperature (ºC)  Time (mm:ss)  
Pre-incubation  95ºC 10:00 mins 
                                                        Amplification (40 cycles)  
Amplification-1  95ºC  00:10 secs 
Amplification-2  60ºC  00:30 secs 
Amplification-3  72ºC  00:01 secs 
Cooling  40ºC 00:30 secs 
 
After the completion of the 40 cycle, the Ct value or the crossing point values (CP) generated 
curves that represent the number of the cycles each sample needed to detect the florescence by 
LightCycler® 480 system. The higher the Ct value, represents lower gene expression; and the 
lower Ct value indicates high expression of the particular gene. These values were then taken 
and used to perform comparative analysis between the expressed genes with the housekeeping 
gene (endogenous control) represented by delta Ct. The delta Ct was measured by subtraction 





between samples were calculated using the formula 2-∆∆Ct that represents the relative 
expression fold change between the genes with and without treatment [137].  
The analysis of Ct value using the equation: 
Ct = PCR cycle 
∆Ct = Ct (gene test) – Ct (endogenous control)  
∆∆Ct = treated (Ct (gene test) – Ct (endogenous control)) – untreated (Ct (gene test) – Ct 
(endogenous control)) 
Relative quantification (RQ) = 2-∆∆Ct  
Relative quantification is fold change of the treated compared to the untreated. For example, if 
the RQ is 2.0, it means the gene is expressed two times more than the untreated one, if RQ is 
0.2 means the expression is 80% less then untreated.  
The data was collected from the LightCycler® 480 system and transferred to Microsoft Excel 
2016 to determine the RQ value from the Ct value. After generating RQ values, they were 
presented in graphical form and analyzed using Graphpad Prism 7. 
 
 
Table 6: RT PCR reagents and equipment  
                                                                  RT PCR  
Material Supplier 
LightCycler® 480 Probes Master ThermoFisher Scientific 
TaqMan® Gene Expression Assays (all probes) ThermoFisher Scientific 
Ambion® Nuclease-Free Water Roche  
LightCycler® 480 system Roche 
384 well PCR plate ThermoFisher Scientific 
 
 
3.3 Protein expression analysis by western blot 
 Cell lysate preparation 
Cells grown to 70-90% confluency were washed with ice cold PBS twice, and lysed in RIPA 
buffer containing 1% Sodium Orthovanadate (SO), 1% protease cocktail inhibitor (PIC), 1% 





After adding lysis buffer, the cells were scraped and lysates were transferred to microcentrifuge 
tubes and incubated on ice for 20 minutes, vortexing every 5-10 minutes. The lysates were 
centrifuged at 12,000 rpm for 10 mins at 4°C to pellet DNA and cellular debris. The 
supernatants were transferred to new tubes using a micropipette and pellets were discarded. The 
supernatants were then used instantly or stored at -80ºC. 
Table 7: Materials used in cell lysate preparation 
Material Supplier 
RIPA Buffer Sigma Aldrich  
PIC  Sigma Aldrich 
SO Sigma Aldrich 
PMSF Sigma Aldrich 
Phosphatase inhibitor cocktail Sigma Aldrich 
 
 
 BCA assay for determining protein concentration 
For quantifying the total protein concentration in the lysate, Bicinchronic Acid (BCA) assay 
was performed using Pierce™ BCA Protein Assay Kit from Thermo Scientific in a 96 well 
plate. The standard curve was generated from the serial dilution from 0 to 2000 µg/ml of the 
BSA standard solution. 5 µl lysates from each sample were added to the plate and 45 µl PBS to 
make a 10X diluted protein sample. BCA mix was made by mixing BCA reagent A (BCA) and 
BCA reagent B (copper sulfate) in a 1:50 ratio. In each well, 50 µl of the BCA mix was added 
and placed on a shaker for 1 minute to mix properly and incubated at 37°C for 20-30min. The 
concentration of the samples was measured at 562 nm absorbance with the plate reader (BioTek 
Instruments). The absorbance values were analyzed using Microsoft Excel 2016 where the BSA 
standard curve was extrapolated to measure protein concentrations of each sample.  
 
 SDS PAGE 
After measuring the sample protein concentration, the lysates were prepared for SDS PAGE 
(sodium dodecyl sulfate–polyacrylamide gel electrophoresis) that separates the protein by 





loading dye (BIO-RAD xt sample buffer, 4x with 5% β-mercaptoethanol). Protein samples 
containing sample buffer were denatured by boiling at 95°C for 10 minutes.  
 
Table 8: Materials used in SDS PAGE 
Material Supplier 
xt sample buffer, 4x BIO-RAD 
Mini-PROTEAN® TGX™ Protein Gels, 20 µl 12 well 
Mini-PROTEAN® TGX™ Protein Gels, 15 µl 15 well 
BIO-RAD 
PageRuler™ Plus Prestained Protein Ladder, 10 to 250 
kDa 
ThermoFisher Scientific 
10x Tris/Glycine/SDS buffer BIO-RAD 
 
Samples were separated on 4-15% gradient Mini-PROTEAN® TGX™ Protein Gels supplied 
by BIO-RAD (12-well with 20 µl sample loading volume or 15-well with 15 µl sample loading 
volume depending on experiment) in 10X Tris/Glycine/SDS buffer. 5 µg PageRuler™ Plus 
Prestained Protein Ladder (10 to 250 kDa from ThermoFisher Scientific) was used as a 
molecular marker (see Table 8). The gel was run for 1 hour at 100V.  
 
 Transfer of protein and immunoblotting  
Following separation on SDS-PAGE, the proteins were transferred to a PVDF membrane also 
by electrophoresis (semi-dry). Transfer buffer in which filter papers were soaked consisted of 
20% ethanol, 20% transfer buffer (Trans-Blot® Turbo™ 5x Transfer buffer by BioRad) and 
60% milQ. The 0.2 µm PVDF membrane was presoaked in MeOH for 5 min.  The separated 
proteins were transferred to the membrane for detection by antibody. The gel was removed 
from its chamber and was activated under UV on the ChemiDoc XRS+ (BIO-RAD). After 
activation, the transfer sandwich was prepared in the follow order from bottom to top: filter 
paper, PVDF membrane, gel and filter paper. The buffer-soaked sandwich was then placed in 





membrane was placed in the ChemiDoc XRS+ again to verify the transfer and record the total 
protein content in the membrane. The membrane was blocked at room temperature with 5% 
non-fat dry milk or 5% BSA in TBS-Tween 0.1% (Sigma Aldrich) for an hour to avoid any 
unspecific binding. For detection of Axl expression, the membrane was incubated with primary 
anti-human Axl antibody (Polyclonal Goat IgG AF154; R&D Systems) in 2% BSA TBST at 
1:1000 concentration overnight at 4°C. Axl antibody from cell signaling Axl (C89E7 Rabbit 
mAb) was also used. The blot was again washed three times for 5 minutes each with PBS-T 
and was incubated with anti-goat secondary antibody (HRP-conjugated anti-Goat IgG, anti-
Rabbit IgG Secondary Antibody from Invitrogen) at 1:5000 or 1:10,000 in 5% milk or BSA at 
room temperature for 1 to 1.5 hour. AB885 from Abcam (Polyclonal Goat IgG)  was used to 
identifying Gas6, diluted 1:500 in TBS-T and anti-goat secondary antibody (HRP-conjugated 
Anti-Goat IgG from Invitrogen) was used as secondary at 1:2000 concentration in 5% milk 
PBST. For detecting GGCX ab106924 from abcam raised in goat was used diluted 1: 2000 in 
2% BSA and anti-goat secondary antibody (HRP-conjugated Anti-Goat IgG source wrong) 
diluted 1: 2000 concentration in 5% milk PBS-T.   
VKORC1 was detected using ab206656 (rabbit monoclonal IgG) at 1: 1000 dilution in 5% milk 
TBST and HRP-conjugated Anti-Rabbit IgG Secondary Antibody (from invitrogen) at 1:10000 
in 5% milk PBS-T. Anti-Vimentin antibody (ab137321) raised in rabbit (polyclonal) was used 
to detect vimentin at 1:50000 dilution in 2% BSA and Anti-Rabbit IgG Secondary Antibody 
HRP conjugated; R&D Systems was used as secondary at a concentration of 1:5000 in 5 % 
milk PBST. For detecting loading control alpha tubulin (Monoclonal Anti-α-Tubulin antibody 
produced in mouse) was used at 1:5000 concentration in 5% BSA and anti-mouse secondary 
antibody (goat anti-mouse IgG-HRP from invitrogen) at 1:10,000 concentration was used as 
secondary antibody. After incubation with secondary antibody, the blots were washed 3X 5 
minutes with PBST or TBST, and the Pierce™ ECL Western Blotting Substrate (mixed 1:1) 
was added for 5 min. However, for stronger signal in short time for proteins with lower 
expression levels, Super Signal West Femto Maximum Sensitivity Substrate (mixed 1:1) was 
used for a few seconds to enhance the signals. The blot was exposed using ChemiDoc XRS+ 






Table 9. Materials used in transfer of protein and immunoblotting  
Material Supplier 
Trans-Blot® Turbo™ Transfer System BIO-RAD  
Trans-Blot® Turbo™ Transfer Buffer BIO-RAD 
Immun-Blot® PVDF Membrane 
Filter paper for Turbo™ Transfer 
BIO-RAD 
Human Axl antibody AF154 
Axl antibody, C89E7 (Rabbit monoclonal antibody) 
R&D Systems 
Cell singling 
HRP-conjugated Anti-Goat IgG Secondary Antibody 
HRP-conjugated Anti-Rabbit IgG Secondary Antibody 
Sigma Aldrich 
Invitrogen 
Gas6 antibody, AB885 (Polyclonal Goat IgG) R & D system 
GGCX antibody, ab106924 (Polyclonal Goat IgG) Abcam 
VKORC1 antibody, ab206656 (rabbit monoclonal IgG) Abcam 
Vimentin antibody, ab137321(rabbit polyclonal IgG) Abcam 
Alpha tubulin (Monoclonal Anti-α-Tubulin antibody 
produced in mouse) 
Sigma Aldrich 
Goat anti-mouse IgG-HRP: sc-2005 Invitrogen 
Pierce™ ECL Western Blotting Substrate ThermoFisher Scientific 
SuperSignal™ West Femto Maximum Sensitivity Substrate ThermoFisher Scientific 






3.4 Functional assays 
 Cell migration analysis using xCELLigence 
Cell migration was studied by xCELLigence technology in real time. The xCELLigence 
electronic real-time cell-sensing assay (RTCA) DP system consists of three components. First, 
RTCA impedance analyzer that provide stations for three 16 well plates inside a tissue culture 
incubator. Second, a display monitor to assess migration using CIM plate 16 on the 
xCELLigence DP analyzer. Third, the 16 well CIM plates that have two chambers separated by 
microporous membrane made with pores on the top and gold electrodes on the bottom. The 
bottom of the CIM (cell invasion/ migration) microwell plates are covered with gold 
microelectrodes in an interdigitated pattern that measures the differences of impedance within 
an electrical circuit. When cell from the upper chamber passes through the 0.8 μm pore in the 
membrane and then adhere to the gold microelectrodes attached to the lower chamber 
containing chemoattractant, the computer with RTCA software generates cell index (CI) values. 
The cell index (CI) is the differences between the impedance at time point n and impedance in 
the absence of cells, divided by a nominal impedance value that is converted into a unit less 
parameter.  This software was used for monitoring live cells as well as for analyzing the data 
generated.  The cell number and cell size can influence the CI value. In the dual-plate (DP) 
format, migration was detected using the change of impedance signals generated by number of 
cell passes pore and attached to the electrode. It can be used to identify cell migration or 
invasion in short or long period of time.  
The RTCA impedance analyzer was placed in an incubator (37°C, CO2 5%, O2 21%). 
However, cells used in the experiments were cultured in a low oxygen incubator (37°C, CO2 
5%, O2 5%). The CIM-Plate is composed of two chambers, upper and lower chamber both 
containing 16 wells. The wells were numbered from top bottom (from A1, A2, B1, B2 ….to H1 
and H2). For migration analysis, 14 wells from A1 to G2 wells of the lower chamber of the 
CIM-plate were filled with 160 μl medium containing 10% fetal bovine Serum (FBS) as a 
chemoattractant. However, the H1 and H2 were filled with serum free media (SFM) as a 
negative control. After filling up the lower chamber, CIM-plate 16 was assembled by placing 
the upper chamber on the top. The chambers were attached carefully by avoiding bubble in 
between the chamber. 30 μl of serum-free medium was added to the 16 wells of the upper 
chamber. After assembling the CIM-Plate, it was placed in the RTCA DP analyzer for 1 hour 






Table 10: Arrangement of CIM-Plate for cell migration 
A1: upper- NZM 3 (20000 cells) in FBS free medium,  
lower- 10%FBS medium  
A2: upper-NZM3 with Vit K (20000 cells) in FBS free 
medium,  
lower-10%FBS medium  
B1: upper- NZM 3 (20000 cells) in FBS free medium,  
lower- 10%FBS medium 
B2: upper-NZM3 with Vit K (20000 cells) in FBS free 
medium,  
lower-10%FBS medium 
C1: upper- NZM 3 (20000 cells) in FBS free medium,  
lower- 10%FBS medium 
C2: upper-NZM3 with Vit K (20000 cells) in FBS free 
medium,  
lower-10%FBS medium 
D1: upper- NZM 6 (20000 cells) in FBS free medium,  
lower- 10%FBS medium 
D2: upper-NZM6 with Vit K (20000 cells) in FBS free 
medium,  
lower-10%FBS medium 
E1: upper- NZM 6 (20000 cells) in FBS free medium,  
lower- 10%FBS medium 
E2: upper-NZM6 with Vit K (20000 cells) in FBS free 
medium,  
lower-10%FBS medium 
F1: upper- NZM 6 (20000 cells) in FBS free medium,  
lower- 10%FBS medium 
F2: upper-NZM6 with Vit K (20000 cells) in FBS free 
medium,  
lower-10%FBS medium 
G1: upper- NZM 3 (20000 cells) in FBS free medium,  
lower- 10%FBS medium 
G2: upper-NZM6 with Vit K (20000 cells) in FBS free 
medium,  
lower-10%FBS medium 
H1: upper- NZM 3 (20000 cells) in FBS free medium,  
lower- FBS free medium 
H2: upper-NZM6 with Vit K (20000 cells) in FBS free 
medium,  
lower- FBS free medium 
 
Table 11: Arrangement of CIM-Plate for cell migration 
A1: upper- NZM 20 (20000 cells) in FBS free 
medium,  
lower- 10%FBS medium  
A2: upper-NZM20 with Vit K (20000 cells) in FBS 
free medium,  
lower-10%FBS medium  
B1: upper- NZM 20 (20000 cells) in FBS free 
medium,  
lower- 10%FBS medium 
B2: upper-NZM20 with Vit K (20000 cells) in FBS 
free medium,  
lower-10%FBS medium 
C1: upper- NZM 20 (20000 cells) in FBS free 
medium,  
lower- 10%FBS medium 
C2: upper-NZM20 with Vit K (20000 cells) in FBS 
free medium,  
lower-10%FBS medium 
D1: upper- NZM 34 (20000 cells) in FBS free 
medium,  
lower- 10%FBS medium 
D2: upper-NZM34 with Vit K (20000 cells) in FBS 
free medium,  
lower-10%FBS medium 
E1: upper- NZM 34 (20000 cells) in FBS free 
medium,  
lower- 10%FBS medium 
E2: upper-NZM34 with Vit K (20000 cells) in FBS 
free medium,  
lower-10%FBS medium 
F1: upper- NZM 34 (20000 cells) in FBS free 
medium,  
lower- 10%FBS medium 
F2: upper-NZM34 with Vit K (20000 cells) in FBS free 
medium,  
lower-10%FBS medium 
G1: upper- NZM 20 (20000 cells) in FBS free 
medium,  
lower- 10%FBS medium 
G2: upper-NZM34 with Vit K (20000 cells) in FBS 
free medium,  
lower-10%FBS medium 
H1: upper- NZM 20 (20000 cells) in FBS free 
medium,  
lower- FBS free medium 
H2: upper-NZM34 with Vit K (20000 cells) in FBS 
free medium,  







Assay were prepared by counting. Four NZM cell lines with and without vitamin K treatment 
were washed with PBS and trypsinized. After trypsinization, the serum containing media was 
added at a 1:1 ratio to neutralize the trypsin.  Then the cells were transferred into a 15ml tube 
for centrifugation at 800g for 5 min and after centrifuging, cells were resuspended in serum-
free medium. The concentration of the cells in the serum free media was determined and was 
adjusted to 20,000 cells/ml by adding required amount of the same media. After incubation and 
background measurement, 100 μl of each cell line was added to the upper chamber to give a 
final of 2000 cells/well. In the bottom 4 wells, G1 and G2 were used as positive controls with 
serum in the lower chamber and H1, H2 used for negative control as previously explained. The 
CIM-plates were left in tissue culture hood for 30 minutes at room temperature to allow the 
cells to settle on the bottom surface of the upper chamber. Then the CIM 16 plates were placed 
in the RTCA DP analyzer inside the incubator and measurements were taken at intervals of 15 
min for 24 hours and sometimes up to 48 hours. After 48 hours (depending on the experiment), 
the impedance values expressed as a CI value generated by the xCELLigence were collected as 
excel files and the data were analyzed by GraphPad Prism 7. All samples were run as three 
technical replicates. (see Table 10 & Table 11) 
 
 Cell proliferation & Spheroid formation assay using IncuCyte 
The incuCyte®ZOOM (Essen Bioscience) system allows continuous and quantitative live cell 
imaging.  In this system, the viable cells are measured in situ in a physiologically relevant 
environment inside the incubator. It has three objectives with magnifications of 4x, 10x and 
20x. The system is fully automated and it takes picture of the plate at required time intervals. 
For the proliferation assay, the 10x magnification was used. The IncuCyte was placed in the 
normal incubator (37°C with 5% CO2). However, the cells were cultured in the low oxygen 
incubator (5% O2, 5% CO2, 37 °C). Thus, instead of having the plates in the IncuCyte culture 
conditions continuously, the pictures were taken on demand relocating the plate briefly from 
it’s usual low oxygen culture condition to the IncuCyte for a quick scan. Cells were counted 
and density adjusted to 2000cells/ml. A 96 well plate (from Thermo Fisher Scientific) was 
mapped for 12 cell lines cultured with and without 22 uM vitamin K. 250 μl (2000cell/ml) of 
each sample was added in wells with 2 technical duplicates (see Table 12). The 96 well plate 






Table 12: Plate map for cell proliferation 
A1     2     3     4     5    6    7    8    9 10 11 12 
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For spheroid formation assay, 200 μl (2000cell/ml) of cells from the same batch were plated in 
ultra-low adhesion round bottom plates (Nunc™ 96-Well Polystyrene Round Bottom 
Microwell Plates from Thermo Fisher Scientifc) specific for spheroid formation. The plate map 
is demonstrated in (see Table 13). The plates were centrifuged at 12000 rpm for 15 minutes and 
were placed in the low oxygen incubator. Both the proliferation and spheroid formation 
experiments were done in parallel. Once daily for 5 days, both plates were transferred to the 
incuCyte®ZOOM and pictures were captured using the scan on demand command. After 5 
days, a software (incuCyte®ZOOM) quantified the cell proliferation and spheroid formation 
assays. The software used an algorithm that analyzed and quantified phase contrast images 
measuring the area covered by cells and converted it to confluence over time values. Graphpad 
Prism 7 was used to graph the proliferation rates of the cells with and without vitamin K. 









Table 13: Plate map for spheroid formation 
     1     2     3     4     5    6    7    8  9 10 11 12 
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3.5 Phospho Axl sandwich ELISA 
The enzyme-linked immunosorbent assay (ELISA) is a method that utilizes antibodies to 
determine and quantify the presence and status (for example phosphorylation) of specific 
proteins. The method was used to detect the phosphorylation of Axl RTK at the residue Tyr866 
and Tyr821 in the intracellular kinase domain. Dr. Lavina Ahmed from BergenBio AS 
standardized the protocol used for detecting phosphorylation at two positions in sandwich 
ELISA; a special type of 96 well white plate (C96 fluronunc from Thermofisher) was used. The 
plates were coated with 100µl/well capture antibody 3,6µg/ml 5F11 against Axl (provided by  
BergenBio) in 200 mM Sodium carbonate/bicarbonate buffer (5,7 g Na2CO3 in 200 ml water 
plus 6,72 g NaHCO3 in 800 ml, pH 9.4-9.6) (dilution  1:1000). The plate was sealed with special 
foil (DMSO Resistant Foil-peelable adhesive foil) and was incubated overnight in 4°C. The 
next day, the plates were washed by aspirating the buffer liquid. Then the plates were blocked 
with 5% milk in TBS buffer and were sealed with the special foil and placed in 37°C incubator 
for 4-5 hours. The plates were then washed two times with 0.05% TBS Tween 20 (TBST) with 
plate washer (from Thermo Scientific multidrop). After the last wash, the plates were dried by 





50 µl of each sample at concentration of 1 mg/mL were added in each well. The standard for 
Axl was also added in five series dilution to the plate.  The plates were sealed with foil and 
were incubated overnight at 4°C. This allows capture of total Axl from the cell lysate. On the 
third day, the plates were washed with 0.05% TBS Tween 20 (TBST) using the plate washer. 
100µl/well pAxl 866 detection antibody at 1:10000 concentration was added in one plate and 
pAxl 821-18 antibody at 1:6000 concentration was added in the other plate. The antibodies 
were diluted in 5% milk in TBS and the plates were incubated overnight at 4°C. On the last 
day, the plates were washed and the secondary antibody (goat anti rabbit from Jackson’s lab 
111-035-144) at 1:16000 dilution was added to the plate for two hours. Finally, the plate was 
washed with TBST and 100µl/well ECL ELISA reagent (ThermoFisher Scientific) chemolumi 
(1 part liquidA: 1part liquid B) was added to develop the plates. After adding the reagent mix, 
the plates were shaken for 1min and read on a plate reader (CLARIOstar® High Performance 
Monochromator Multimode Microplate Reader from BMG LABTECH) to read the absorbance 
at 450-595 nm. Using an integrated software in the computer, the absorbance was collected as 
excel data sheet. GraphPad Prism 7 was used to make graph from the data. 
 
3.6 Mass cytometry (CyTOF- time of flight mass spectrometry) sample preparation 
Flow Cytometry is a well-established method for analyzing multiple markers on single cells 
[138]. Recent development of mass spectrometry leverages the precision of data analysis from 
flow cytometry. Cytometry by time-of-flight (CyTOF) is the fusion of the two methods. With 
mass cytometry, it is possible to measure more than 40 features of one single cell including 
antibody based determining of surface protein and intracellular protein, detecting RNA and 
DNA based on nucleotide amplification, and measuring cell cycle of a single cell [139]. Flow 
cytometry uses photon optics for detecting fluorophore generated by the sample and in contrast, 
the mass cytometry use chelated metal ion tag conjugated with antibody that detect in the atomic 
mass spectrometry [140]. 
 
 Cisplatin labeling 
Working solution of the viability reagent, cisplatin (Fluidigm) was prepared fresh on the day of 
the experiment by diluting the 5mM stock solution into cell media (RPMI 10% FBS) at a 
concentration of 1:20000. Cells were trypsinized and centrifuged at 1200 rpm for 5 minutes. 





tube containing the cells and incubated for 5 minutes. The cells were mixed properly by 
vortexing and then 5ml of cisplatin free media was added and centrifuged for 220g for 5min. 
The cells were then fixed with 1 ml of PFA (1.6% PFA in PBS) and after incubation for 10 
minutes at room temperature, they were spun down in Eppendorf tubes, supernatant was 
removed, and the pellet was kept in -80C until use. 
 
 Barcoding 
In a 96-well plate, each sample was resuspended in 200 µl of Perm Buffer and centrifuged at 
300-600g for 3 minutes. The pellets were again resuspended in 195 µl of Perm Buffer and 5µL 
of barcoding solution (Cell-ID 20-Plex Pd Barcoding Kit from Fluidigm, contains Perm buffer 
and cell staining media, CSM) was added to each well and incubated for 30 min at RT.  Cells 
were centrifuged at 300g for 4min and the pellets were gradually washed with Perm buffer and 
CSM (twice each). 
 
 Antibody staining 
One sample from each of the columns were pooled into Eppendorf tubes containing CSM and 
permeabilized for 20min in 200µl of ice cold methanol at -20°C. The cells were washed twice 
in 1mL CSM and then were stained with antibody mix (antibody against the protein of interest). 
The pooled sample was stained into with 100µl for 1h at RT. After antibody incubation, cells 
were washed 3 times in CSM and ware intercalated overnight at 4°C or 30 min at RT with 
Iridium: 0.3µl diluted in 1ml PBS with 1.6% PFA. (Abcam). The cells were then washed twice 
with PBS and finally with miliQ water. The cells were resuspended in MilliQ water 106 cells/ 
ml, filtered in FACS filter tube, 100µl/ml of calibration beads were then added for 
normalization post data collection. 
 
 CyTOF measurement 
The cell sample mixtures were inserted and analyzed using the CyTOF® mass cytometer 
(Helios from Fluidigm). The data was generated from each channel as FCS files. The FCS files 





3.7 Statistical analysis 
All the statistical analysis of this study was done using the Microsoft Excel 2016 and Graph 
Pad Prism 7.3. In graph Pad Prism, student t-test was implemented to compare two groups of 
data. For QPCR, the scales used for X and Y were linear but a Log10 scaled was also used if 
the values were widely spread. The Pearson correlation coefficient (Pearson's r) was used 
determine the linear correlation between the between two different variables. The correlation 
coefficient “r” measures the strength and direction of the linear relationship between data on an 
X-Y scatterplot. The value of Pearson's r +1 reflects a positive correlation between the variables. 
Whereas, the Pearson's r value -1 represents a negative correlation. The value 0 reflects no 
correlation. In the experiments, the values between 0.5 < r < 1 and -1< r < -0.5 are counted as 
significantly correlated. The R-squared vale is a statistical measure of how close the data are to 
the fitted regression line and this was also plotted in our graphs along with 95%confidence 
interval bands, curved lines adjacent to the line, which are the boundaries of all possible fitted 
straight regression line lines (information studied from Graphpad prism 7.3).  
Statistical significant difference between the treatment and untreated groups were determined 
using null hypothesis and the alternative hypothesis that represents zero difference and 
significant difference respectively. The P value generated by the t-test differentiate the result as 
null or alternative hypothesis. P value (Noted in the text and figures as *P < 0.05, **P < 0.01, 
***P < 0.001, ****P < 0.0001) was considered as the statistical significant result. *P < 0.05 
means a 5% chance that the observed result is not significant. The P value more than 0.05 was 
considered a non-significant result. Similarly, ****P < 0.0001 means highly significant result 
and the hypothesis is true. The graphs were made using the standard error of the mean (SEM) 
values that represents the spread of the sample mean value. One-way ANOVA was used to 
determine the statistical significance between two or more groups, such as with our qPCR data 
determining the effects of culture conditions and treatments. The two-way ANOVA was used 
to determine the proliferation and migration significance compared to comparing multiple time 






4 Results  
4.1 Expression analysis of NZM cell lines  
 Expression of Axl and Gas6 in NZM cell lines 
Western blotting was used to characterize Axl and Gas6 protein expression in 20 NZM cell 
lines and one CRISPR Axl knockout NZM line (NZM17 Axl -/-). The method used for 
preparing the cell lysates for analysis is described in section 3.3.  The blot showed that NZM9 
and NZM17 have high Axl expression compared to the other cell lines. NZM 17 Axl-/- was 
used as negative control (see Figure 17). All of the NZM cell lines had Gas6 expression. NZM 
30, NZM 34, NZM 46, NZM 55, NZM 61, NZM 63, NZM 100 show low Gas6 expression 
compared to the other lines. Antibodies used to probe Axl and Gas6 were Anti-Axl AF154 
(R&D) and Anti-Gas6 (Abcam) respectively. 
 
Figure 17: Western blot of Axl and Gas6 expression in the 20 NZM cell lines plus one Axl knock out 
line with alpha-tubulin as a loading reference. The blot representing Axl and Gas6 from NZM 1 to NZM 








 mRNA expression level of AXL, GAS6, GGCX and VKORC1 in 20-melanoma cell 
line and their correlation with clinical outcome 
qPCR was used in addition to western blotting to check Axl and Gas6 expression at mRNA 
level in 20 NZM cell lines, along with the expression of other genes of interest. The method 
used for isolating and preparing RNA for analysis is described in section 3.2. In addition, we 
wanted to determine any correlations between the expression levels of various Axl and vitamin 
K related genes with clinical outcomes of patients from whom these cell lines were derived. 
The levels of AXL, GAS6, GGCX and VKORC1 transcripts (Figure 18 & Figure 19) were 
measured by qPCR. The clinical data available for us to explore included time to lymph node 
metastasis, distant metastasis and overall patient survival. qPCR denoted the number of DNA 
replication cycles taken by the genes to be expressed. The cycles were extracted and using an 
equation (described in 3.2.5) in Microsoft Excel the CT values were measured that show the 
expression of all the genes in different NZM cell lines relative to the housekeeping control. 
High CT values meant the expression of the particular gene was low. To determine relative 
expression of genes between cell lines fold change was measured against the cell line with 
lowest expression of the respective gene. Fold changes were then plotted against clinical 
outcome. However, CT values were always considered before data analysis to ensure that fold 
changes were biologically meaningful. 
AXL expression varied among the NZM lines with CT values ranging from 17.72 to 32.29. 
NZM 9, NZM 17 showed highest AXL expression with CT value of 17.72, and 20.09 
respectively, while NZM 20 showed lowest AXL expression with a CT value of 32.29. The CT 
value for NZM 100 was excluded from the result because it generated an error in the PCR 
reaction believed to be due to the interference of melanin bound RNA.  
CT values for GAS6 ranged from 24.77 in the NZM 17 to 33.01 in NZM 20. Among the 20 cell 
lines, nine showed negligible CT values over 30 indicating that expression is almost 
nonexistent. Expression of GAS6 seems to be very high in a subset of cells and either very low 
or nonexistent in most cells (Figure not shown).    
NZM 34 had highest expression of GGCX with CT value 24.38 and lowest expression was seen 
in NZM 11 with a CT value 34.6. It must be noted that as with AXL and GAS6, expression of 
GGCX in NZM 20 was also very low with CT value 25.53. 
VKORC1 expression was highest with CT values 21.37 and 21.68 in NZM 55 and NZM 34 
respectively in comparison to the lowest CT value 28.64 in NZM 11, matching the trend seen 





the expression of between GGCX and VKORC1 among these cell lines (r = 0.7, r2 = 0.5, 
p=0.0004) (Figure 18) (Table 14) 
 
 
Figure 18: Correlation was between expression of GGCX and VKORC1 in 20 melanoma cell lines 
 
Table 14: The values calculated from the graph showed the Pearson r and P values that are significant. 
 GGCX VS VKORC1 
 R 0,7305 
95% Confidence Interval 0,4135 to 0,8895 
r squared 0,5336 
P (two-tailed) 0,0004 
 
Values closer to 1 are considered for data that are more positively correlated. It was 
demonstrated that the GGCX and VKORC1 have higher correlation then the others with r value 
of 0.7305 (Table 14). No significance was found between the expression of GGCX or VKORC1 
with AXL expression (not shown in figures). 
 
 Exploring the correlation between the expression AXL, GAS6, GGCX and VKORC1 
with the clinical outcome 
Although the data was not always distributed for regression analysis it appears that the subset 
of lines with higher GGCX, Axl but not GAS6 expression showed faster spread of the diseases 





Regression analysis indicated a negative correlation between GGCX expression and overall 
survival, and lymph node metastasis. Patients had shorter survival, and faster spread of the 
disease to the lymph node and distant organs when the cells had high expression of GGCX 
(Figure 20). Although not a statistically significant there also appears to be some negative 
correlation between VKORC1 expression and overall survival (Figure 21) (for Pearson’s r 





Figure 19: mRNA expression levels of AXL against overall survival, of the patient time to lymph node 






Figure 20: mRNA expression levels of GGCX against overall survival, of the patient time to lymph 
node metastasis, to distant metastasis, and time from the lymph node metastasis to distant metastasis 
 
Table 15: The values calculated from the graph showed the Pearson r and P values that are 
significant. 
 GGCX VS OS AXL VS LN to DM VKORC1 VS LN 
 R -0,5177 0,6246 -0,5437 
95% Confidence Interval -0,6746 to 0,1595 0,2057 to 0,85 -0,1249 to -0,8018 
r squared 0,2680 0,3901 0,2956 







Figure 21: mRNA expression levels of VKORC1 against overall survival, of the patient time to lymph 
node metastasis, to distant metastasis, and time from the lymph node metastasis to distant metastasis 
 
4.2 The effect of culturing NZM cell lines in vitamin K  
As described in the introduction of this thesis, vitamin K works as a cofactor for activating the 
enzyme GGCX. GGCX further promotes the activation of the Gas6 via the vitamin K dependent 
γ-carboxylation of its Gla domain.  This involves the vitamin K dependence by converting 
glutamate to γ-carboxyglutamate. Gas6 activation is thought to further activate Axl [126]. In 
order to assess the effect of vitamin K on the NZM cell lines, 13 of the 20 cells were cultured 
in 22 uM vitamin K (Roche) for at least one week.  11 of these were cell lines that carried BRAF 
mutations and already part of an ongoing project in the Loren’s laboratory focused on 
understanding resistance to BRAF inhibitors. We included one non BRAF-mutated cell line, 
NZM 46 as it had the highest expression of GGCX and hence was of interest. NZM 61 and 63 





Barring the addition of vitamin K, cells were cultured as usual in low oxygen incubator (5% 
O2, 5% CO2, 37°C) to mimic the endogenous physiological low O2 level in tumor, which range 
from 2–5% [141].  
 
 
Figure 22: Images of the five NZM cell lines (100× magnification Nikon ECLIPSE TS100) selected 
randomly from all twenty cell lines. 
 
The morphology of the cell lines varied with and without vitamin K (Figure 22). The cells 
appeared to be more epithelial-like and others more fibroblastic-like before the treatment of 
vitamin K (Figure 22). However, when they were treated with vitamin K, were observably more 
rounded or irregularly shaped. Cells cultured in vitamin K also seemed to proliferate slower 
and this was further investigated and described in section 4.2.1.  
 
 Cell culture media contained live floating cells when cultured in vitamin K 
An interesting observation was that a small but noticeable number of cells appeared to become 
non-adherent when the NZM cells were cultured in vitamin K.  These cells were first noticed 





NZM 46, NZM 76, NZM 61, NZM 63 and NZM 100, cells from the culture medium was 
collected, centrifuged, and counted to analyze the live cell percentage. Counting of the cells 
was performed using the Countess automated cell counter from Invitrogen. Tryphan blue was 
used to determine live and dead cell (see section 3.1.6). Results from the counts showed that 
the cell culture medium from the vitamin K treated cells contained a significantly larger number 
of live cells than cells culture medium from the control group.  The absolute counts and percent 
live cells in each sample are shown in Figure 23. These counts have been repeated and 
confirmed by another member of the laboratory, Dr Kjersti Davidsen.  
 
Figure 23: Cell count of the five NZM cell lines in media that are treated and untreated with 
vitamin K. 
 
 Expression of plasticity markers in NZM cell lines cultured in vitamin K and 
BGB324 
To assess the effect of vitamin K and BGB324 at an mRNA and protein level, qPCR and 
western blot respectively were performed for five NZM cell lines. Expression of twelve genes 
was assessed in NZM3, NZM4, NZM6, NZM20, and NZM34. The cell lines were selected 
according to their AXL, GAS6 and GGCX expression determined from the aforementioned 
qPCR results. The expression of genes analyzed following culture in vitamin K and BGB324 
included the TAM receptors Axl and Tyro3, it’s ligand Gas6, GGCX the enzyme for γ-
carboxylation, it’s transcription factor NF1X, plasticity markers Zeb1, Zeb2, vimentin, N-
cadherin, Slug, transcription factor shown to be related to Axl, melanogenesis specific gene 





 NZM 3 
Changes in the expression pattern of six of 12 genes examined were seen when NZM 3 was 
cultured in vitamin K, BGB324 or in a combination of both. Culturing them in vitamin K 
resulted in approximately two-fold significant increased transcription of AXL, ZEB1, N-
CADHERIN (CDH2) with p value 0.005, 0.016, 0.0001 respectively (Figure 24a, 24g and 24k) 
and reduced transcription of GAS6 and E-CADHERIN (CDH1) with p value 0.0021 and 0.0024 
respectively (Figure 24b and 24l). These changes were sustained when cells cultured in vitamin 
K and were treated with BGB324: this included a 2.5 fold increase in expression of AXL, ZEB1 
and N-CADHERIN (p=0.0018, 0.0005, and 0.0001) (Figure 24a, 24g and 24k) and decreased 
of GAS6 and E-CADHERIN (p=0.005, 0.0078) (Figure 24b, and 24l). The only difference here 
was a decrease in GGCX expression observed when cells cultured in vitamin K and were treated 
with BGB324 (p=0.0011, Figure 24c). With BGB324 treatment alone, only ZEB1 expression 
increased (p=0.021, Figure 24g).Western blot showed a visible decrease in VIM expression only 
when the cells were treated with BGB324 alone (Figure 25). This decrease was also seen at a 
transcript level, although it was not statistically significant (p =0.084).  
 NZM 4 
Almost all the twelve genes were transcriptionally upregulated in NZM 4 cultured in vitamin 
K except for GAS6 which was downregulated (p=0.0006) and no difference seen in MITF 
expression (Figure 24b and 24d). Significant increases were found in the expression of plasticity 
related genes AXL, GGCX, TYRO3, ZEB1, ZEB2, VIM, SLUG, and N-CADHERIN (CDH2) with 
p value 0.0001, 0.0016, 0.008, 0.02, 0.0001, 0.003, 0.0001, 0.0035 respectively (Figure 24a, 
24c, 24f-k). With  BGB324 treatment in presence of vitamin K most of these genes except for 
GGCX remained upregulated, AXL, TYRO3, ZEB1, ZEB2, VIMENTIN, SLUG and N-
CADHERIN (0.0001, 0.0148, 0.0086, 0.0038, 0.0024, 0.0019, and 0.0035 respectively) (Figure 
24a, 24c, 24g-k). The expression of GAS6 mRNA decreased with BGB324 treatment in vitamin 
k (p=0.0012) (Figure 24b). With BGB324 treatment alone the expression of all the genes 
remained unchanged, except for a downregulation of N-CADHERIN (p= 0.0056) (Figure 24k). 
Western blotting showed an increased expression of AXL and decreased expression of GGCX 
when the cells were cultured in vitamin K but not when the vitamin K cultured cells were treated 






 NZM 6 
A downregulation of MITF (p=0.0006), VIMENTIN (p=0.035), E- CADHERIN (p=0.0025) and 
upregulation of AXL (p=0.0002) was found when NZM 6 in presence of vitamin K (Figure 24d, 
24i, 24l, 24a). Treatment with BGB324 in vitamin K showed a similar increase in AXL 
(p=0.0004) and SLUG (p=0.02) and decreases MITF, VIMENTIN, N-CADHERIN and E-
CADHERIN (p=0.0003, 0.02, 0.009, 0.03) (Figure 24a, 24j, 24d, 24i, 24k-l). Western blotting 
also showed an increased expression of Axl when cells were cultured in vitamin K regardless 
of the presence of BGB324 (Figure 25). Treatment with BGB324 alone showed a decrease in 
GAS6, VIMENTIN and N-CADHERIN (p=0.0001, 0.0024, 0.0034) transcripts and an increase 
in ZEB1, ZEB2 and SLUG (p=0.02, 0.03, 0.04) transcripts (Figure 24b, 24i, 24k, 24g-h, 24j). 
 NZM 20 
There is almost no evidence before for AXL expression in NZM 20 using western blot or qPCR. 
However, with the vitamin K treatment AXL (p=0.0059) as well as SLUG (p=0.0006) and N-
CADHERIN (p=0.05) transcription increases and GAS6 (p=0.02), VIMENTIN (p=0.02), E-
CADHERIN (p=0.03) expression decreases (Figure 24a, 24j-k). No significant differences in 
transcription was found with treatment of BGB 324 in vitamin K except downregulation of 
ZEB2 (p=0.004) and VIMENTIN (p=0.001) (Figure 24h, 24i). Downregulation of GAS6 
(p=0.0001), VIMENTIN (p=0.006) and N-CADHERIN (p=0.05) was found when cells were 
treated with BGB324 only (Figure 24b, 24i, 24k). Western blotting showed evidence for Gas6 
and strongest GGCX expression among the five cell lines examined. The western blot showed 
that GGCX expression remained unchanged with BGB324 treatment but decreased when the 
cells were cultured in vitamin K regardless of BGB324 (Figure 25).   
 NZM 34 
NZM 34 showed increased AXL, TYRO3, VIMENTIN, N-CADHERIN transcription (p=0.0001, 
0.005, 0.005, 0.003) (Figure 24a, 24f, 24i and 24k). Treatment with BGB324 did not seem to 
render this effect in vitamin K where a significant increases the expression of these genes 
continued to remain sustained along with other; AXL, TYRO3, ZEB2, VIMENTIN, SLUG and 
N-CADHER with p value 0.0002, 0.0001, 0.03, 0.003, 0.003, 0.03 respectively (Figure 24a, 24f, 
24h-k). BGB324 treatment alone resulted in the upregulation of ZEB2 and SLUG (p=0.007 and 
0.05) (Figure 24h and 24j).  Western blotting showed that the Axl protein expression level was 
strongest among the five cell lines examined and signals appeared to be too saturated to 





expression decreased when cells were cultured in vitamin K and were remained decreased with 
BGB 324 treatment (Figure 25).   
 
Figure 24: The validation of the fold change expression of different marker genes by qPCR. The fold 
change correspond to the treatment with vitamin K and BGB324 of five different cell lines. Section a,b,c  
represents the  Axl, Gas6 and GGCX respectively. d,e,f,g,h,i represents the plasticity markers ZEB1, 
ZEB2, VIMENTIN, SLUG, E-CADHERIN, N-CADHERIN respectively. j and k are transcription factors 
NF1X, MITF, however, TYRO3 is a TAM receptor. The number of stars on the top of the bar means the 






Figure 25: The western blot represents the effect of vitamin K and BGB324 in protein level.  
 
4.3 Functional assays    
 The effect of vitamin K on melanoma cell proliferation  
The proliferation rate of twelve NZM cell lines was measured using the IncuCyte® Live Cell 
Analysis system as described in section 3.4.2. The machine was available for use in a normal 
incubator (21% O2, 5% CO2, 37ºC) but as previously noted NXM cells are cultured under low 
oxygen (5% O2, 5% CO2, 37ºC). In order to maintain the culture conditions but still monitor 
proliferation, the plate was removed from the low O2 incubator and placed into the IncuCyte 
for 2-4 minutes to capture images on demand. Picture was taken every day for 5 days. Cell 
density was determined by the IncuCyte software which assessed density based on confluence. 
Sine the same algorithm was to be translated to all the cell lines, confluence was thought to be 
a more appropriate measure than cell count as different cells lines had different sizes and shapes. 
Graphs representing confluence were drawn on the GraphPad Prism7 software using those 
values generated by the IncuCyte software. 
Figure 26 represents the proliferation rate of the 12 NZM cell lines cultured with and without 
vitamin K. It was found that all the cell lines except NZM 11 and NZM 17 had decreased 
proliferation in Vitamin K. NZM 4, NZM 76, NZM 6 had decreased proliferation when cultured 
in vitamin K (p <0.0001).  In contrast, NZM 3 and NZM 11 showed an increase in proliferation 
when cultured in vitamin K (p = 0.048, p=0.035 respectively) but this was relatively not as 






Figure 26: Proliferation rate of NZM cell lines cultured with the vitamin K. Cell confluence over 5 days 
as measured by the developed algorithms on the IncuCyte software. The P values were measured using 
Prism7. *P < 0.05, **P < 0.01, ***P < 0.001, ****P<0.0001 represents statistically significant 
differences. The X-axis shows the time (120 hours) of proliferation and Y-axis represents fold change. 





 Migration analysis of NZM cell lines cultured in vitamin K   
Cell migration assays were performed in the xCELLigence system located in a normal oxygen 
incubator (21% O2, 5% CO2, 37ºC). The plates were placed in the xCELLigence for over 25 
hours to investigate the effect of vitamin K in four NZM cell lines. Within 25 hours values 
representing the number of migrating cells were generated by the xCELLigence  software using 
cell index (CI) at a 15 minutes intervals.  
After 25 hours, the CI values generated likely represnted proliferation rather than migration. 
Within the 25 hour duration, it was found that the NZM 3 and NZM 20 in vitamin K migrated 
significantly faster (p=0.0204 and 0.0001 respectively). No significant differences in migration 
were determined in NZM 6 and NZM 34 regardless of the presence of vitamin K (Figure 27).  
 
  
Figure 27: Migration rate of cells cultured with the vitamin K. The red and blue lines indicate CI of 
cells cultured with and without vitamin K respectively. The P values significance difference overtime 
of the NZM 3 cell lines and the p value for NZM 20 after 25 hours were represented. However, NZM 6 
and NZM 34 did not show any significance (no showed in figure). Representative graphs shown from 
two biological repeats. The X-axis and Y-axis corresponds time and migration respectively. *P < 0.05, 






 Spheroid formation NZM cell lines cultured in vitamin K   
Spheroid formation was examined using the IncuCyte® Live Cell Analysis system system in 
the same manner as described in section 3.4.2 where the assay was run under low oxygen 
conditions but the plate was relocated to the IncuCyte system once a day where 3-4 minutes 
were used to capture one image per well  at 10X magnification for 5 days. Cells were plated in 
duplicates as described in methods. The spheroid forming cells were determined by monitoring 
the cell ability and rate to form spheroids. Cell culture medium and vitamin K was replaced 
every two days. 
Images of spheroids at each time point are shown in spheroid formation assay. NZM 17, NZM 
6, NZM 76, NZM 9, NZM 4, NZM 11 NZM 55 with vitamin K appeared to start forming 
spheroid faster as presented by the loss of cell aggregate like appearance to a smoother texture 
representing curvature and more regularly rounded edges respectively. The NZM 55 and NZM 
17 in particular formed spheroids much faster in vitamin K from day 2. NZM 34, NZM 30, 
NZM 3 and NZM 20, NZM 46 did not show any obvious differences in spheroid formation 










Figure 28:  Spheroid formation assay for five days of NZM 17, NZM 6, NZM 76, and NZM 9 cell lines 






Figure 29: Spheroid formation assay for five days of NZM 4, NZM 11, NZM 55, and NZM 34 without 






Figure 30: Spheroid formation assay for five days of NZM 30, NZM 3, NZM 46, and NZM 20 without 





4.4 High dimensional Mass cytometry trial run of NZM 7 treated with vitamin K 
A current ongoing project in the Prof. Loren’s laboratory is to underestand intracellular 
signalling cascades using mass cytometry. All 21 NZM lines mentioned in this thesis cultured 
in various conditions including vitamin K and BGB324 have been prepared for CyTOF analysis 
as descibed in section 3.6. A trial run on the Helios cyTOF system (Fluidigm) has been carried 
out with NZM 7 cell line cultured with and without vitamin K (but no floating cells had been 
collected at this point) to analyze phosphorylation and expression levels of 25 proteins (Figure 
31). The signalling panel included heavy metal linked antibodies against human proteins p-
SHP2, cleaved Caspase3, p-Stat3, p-Stat5, PD-L1, p-Stat6, p-EGFR, p-Stat1, p-AKT, 
Vimentin, p-38, E-cadherin, p-MAPKAPK2, p-Erk1-2, p-PLCγ2, IFNγ, p-NFkB, YAP, Axl, p-
S6, CD-44, p-Creb, CD-133, GFP, EGFR (“p” indicating phosphorylation). The panel was 
previously designed by  PhD candidate Maria Lie, Dr Kjerstii Davisen and Dr. Stacey D’mello 
from the Prof. Lorens laboratory with specific research interests in their mind.  The results 
showed a minor change in expression levels of various proteins when cells were cultured with 
vitamin K. The largest differences in upregulation were seen in Axl , vimentin and p-S6 , 
calculated transformed ration of median value of 0.26, 0.29, 0.24 respectively. However, p-
Erk1-2, pNF-kB, p-PLCγ2 showed down regulation in the vitamin K treated with ratio 0.24, 
0.22, 0.18 respectively (Figure 32). This was a pilot study and further optimization is needed to 
validate the result and optimize antibody concentrations. 
 
  
Figure 31: Heat map of the 25 protein expression explained previously. The top row represents the 






Figure 32: Histograms comparing protein expressions between NZM 7 treated with (front) or without 
vitamin K (back), colored according to transformed ratio of medians using the first row as control. The 
data is transformed using an arcsinh transformation with a cofactor of five. 25 different proteins named 
in the X-axis of the histogram were analyzed to see the expression difference with and without vitamin 






Malignant melanoma is a highly aggressive cancer with high prevalence of somatic mutation 
(400 mutations/Mb). The somatic mutations are mostly caused by the exposure to carcinogens 
such as UV radiation. 70% of all melanomas harbors BRAFV600E, NRAS, GNAQ, GNA11, 
MEK1, KIT (MAP2K1), CTNNB1 mutations. These mutations are either driver mutation or 
passenger mutations that consist the bigger potion of the 400 mutation/Mb burden. This huge 
mutational burden makes the malignant melanoma harder to treat with conventional therapies 
[12, 142]. Targeted therapies such as BRAF inhibitors show promising improvements in the 
beginning but over time patients acquire resistance [143]. Abnormal expression of different 
tyrosine kinase receptors has been associated with drug resistance. Drug resistance is acquired 
by altering of the signaling pathway regulated by these RTKs [144]. In this study, cell lines 
derived from metastatic melanoma of New Zealand patients were used to study disease 
progression and resistance to therapy at a molecular level.  
 
5.1 Expression of Axl and Gas6 in NZM cell lines 
Expression of Axl RTK and its ligand Gas6 at a protein and RNA level were determined by 
western blot and qPCR. The western blot showed high expression of Axl in melanoma cell lines 
NZM 17, NZM 9 but was not sensitive enough to detect lower levels of Axl seen from our 
qPCR results. Gas6 was seen to be expressed at the protein level in most of the cell lines 
although up on close consideration we later questioned the integrity of the antibody used here. 
Most interestingly, a signal was detected at approximately 210- 220 KDa that suggested the 
existence of Gas6 prebound with Axl. The molecular weight of Gas6 is 75 kDa but when 
probing for Gas6 by western blot additional high molecular weight bands were seen in all 
samples at approximately 200-kDa position (Figure 33). The molecular weight of Axl is around 
120 kDa. One possible explanation is that these bands may be a result of Gas6 pre-bound to 
Axl on the cellular surface. This has been previously reported in the Lemke group who were 
the discoverers of the TAM receptors. They report that the Axl RTK usually exists in a state 
where Gas6 is pre-bound and that phosphatidylserine is needed for the activation of the receptor 
in this state [79]. In addition, they also report that when Axl is knocked down, Gas6 protein is 
not detectable but transcription remains unchanged. This suggests that since Gas6 is a secreted 
soluble ligand, its detection in the cell may be lost when it does not bind to Axl [79]. However, 





student tested this antibody (ab885 from Abcam) and she showed that this antibody was not 
able to detect recombinant human Gas6 purchased from R&D, which made its specificity 
questionable [145]. An alternative antibody (MAB885) against human Gas6 was not able to 
detect Gas6 in cell lysates but successful detected the recombinant human Gas6. Among 20 cell 
lines, 9 of them (NZM 1, NZM 2,  NZM 3, NZM 7, NZM 11, NZM 20, NZM 30, NZM 55 and 
NZM 61) have very high CT value representing Gas6 expression. This again suggests that the 
western blot signals are not specific for Gas6. 
Previous studies have shown that Axl exists not only as a transmembrane receptor, but also in 
soluble form consisting of the cleaved extracellular domain (soluble Axl, sAXL) with a 
molecular weight of 80 KDa, detectable in the growth medium. Other studies showed that sAXL 
competes for Gas6 binding with the Axl receptor [146, 147].  Cell culture medium was collected 
during our experiments and this is currently being examined for the presence of sAXL and Gas6 
in free or bound form.  Immunoprecipitation and ELISA methods could also be used in the 
future to capture these proteins determine their interaction.  
At an mRNA level, all cell lines except NZM 20 expressed Axl with CT value less than 30. In 
agreement with the western blot results, NZM 17 and NZM 9 showed highest expression of Axl 
among the 20 lines. Expression of Axl in these two cell lines were over a thousand fold higher 
than the other cell lines and we therefore needed to use a log scale to represent the data (Figure 
19). This high expression might be explained by gene amplification. Moreover, a study by 
Shaffer et al. recently showed a large variation in transcription levels of certain genes, including 
AXL in melanoma cells. Distinct cell in single population expressing high AXL levels acquire 
drug resistance [148]. One might speculate that cell lines with high AXL expression have a 
higher propensity to acquire drug resistance.  
Our results show a discrepancy between the qPCR and western blot expression data suggests 
regulation of expression at a posttranscriptional level. The microRNAs miR-34a and miR-34c 
reported to target AXL mRNA. Deletion of the miR-34 binding site in the AXL 3′ UTR region 
of the mRNA reinstated Axl protein levels [149].The presence of these miRNAs could be 
determined using qPCR. It is also possible that only a small subset of cells express Axl 
expression and that this is averaged out and hence not detectable by western blotting [148]. 







Figure 33: Higher molecular weight bands at approximately 200kDa. Possibly Axl-Gas6 complex.  
 
5.2  GGCX but not Axl and Gas6 expression showed correlation with poor patient 
prognosis  
As previously noted, the vitamin K dependent γ-carboxylation of Gas6 by GGCX facilitates its 
activation (section 1.6) which is hypothesized to increase Axl activation and signaling [86]. 
Previous published work has shown that the overexpression of Gas6 and Axl correlates with 
increased cancer invasion, metastasis and poor patient prognosis in a number of cancer types 
[150] including glioblastoma [106].  A recent study has demonstrated a decrease in cancer 
incidence in patients treated with warfarin. Warfarin inhibits the recycling of vitamin K epoxide 
to vitamin K (described in 1.7) [126]. However, the expression of GGCX and other vitamin K 
cycle enzyme VKORC1 has not been previously explored in the context of cancer. In light of 
these findings, we used qPCR to investigate whether the expression of GGCX and other vitamin 
K cycle enzymes had any association with clinical outcome in the melanoma cell lines. Our 
qPCR results demonstrated that although AXL and GAS6 expression did not correlate with 
clinical outcome, expression of GGCX correlated to some extent with shorter overall survival 
(r= -0.5177, p<0.03). It is therefore likely that Gas6 γ-carboxylation and subsequent Axl 





except for some correlation with lymph node to distant metastasis no correlation was observed 
between the expressions of Axl or Gas6 with clinical outcome (Figure 36) but rather that the 
activation status of these two molecules are more relevant in this context. In order to further 
support this finding, Axl activation and signaling downstream are currently being investigated 
using ELISA and CYTOF respectively. Gas6 γ-carboxylation is being determined using 
western blotting and mass spectrometry.  
The Broad Institute Cancer Cell Line Encyclopedia (CCLE) was used to investigate correlation 
between genes of interest in melanoma using previously deposited RNAseq data. GGCX 
expression was profiled in 40 different cancer types where melanomas appeared in the top 4 
(Figure 34). Previous reports have shown that expression AXL inversely related to MITF 
expression and this correlated with metastatic melanoma progression and drug resistance [48]. 
Low MITF/AXL ratio has been associated with increased drug resistance in melanoma. This 
trend was reflected in scatter plots created from the Broad Institute database where MITF 
negatively correlated with AXL expression in the 63 melanoma samples. Interestingly, a 
negative correlation was also observed between MITF and NFIX, the transcription factor of 
GGCX (Graph A & B Figure 35) [151].  
 





There is also evidence for a positive correlation between NFIX and AXL expression (Graph C 
Figure 35). These associations point to a link between the Axl and vitamin K systems. Although 
these correlations of NFIX with AXL and MITF are not apparent with GGCX (Graph D Figure 
35), this may be dependent on the vitamin K present in the system. As seen from this thesis and 
others in this group [145] GGCX expression decreased with the presence of vitamin K, as does 
GAS6 expression. In light of this it is interesting to note the negative correlation between GGCX 
and GAS6 expression in the 64 melanoma samples and recall that the decrease in GAS6 
expression seen in this study in the presence of vitamin K. The correlation between AXL and 
GAS6 expression in these melanoma samples is also noteworthy, here as in our data there also 
appears to be a subset of samples with high GAS6 expression that have high and low AXL 
expression (Graph E & F Figure 35).  
 
Figure 35: Scatter plot from deposits at the Broad Institute showing correlation between different gene 





5.3 The effect of vitamin K on morphology and gene expression in melanoma cell lines 
The importance of the effect of vitamin K on Axl activation was highlighted by Haaland et al 
[126].  Following from this we treated the melanoma cell lines with 22μM vitamin K (decided 
upon from previous studies in blood coagulation-refer to the Blood paper). It was hard to 
confirm the complete absence of vitamin k in the control cell culture conditions but lack of γ-
carboxylation of proteins in these cells was demonstrated by blot by another member of the 
Prof. Loren’s laboratory [145]. We first observed that the cells appeared morphologically 
different when cultured in vitamin K, with a fibroblast-like rounded membrane rather than a 
classic dendritic morphology of a melanoma cell.  A number of cells rounded and peeled off 
the culture surface and many cells appeared to be floating in cell culture media. These floating 
cells were confirmed to be alive (Figure 22). One research group has described this as a highly 
migratory amoeboid phenotype and in the context of cancer; this represents mesenchymal-
amoeboid transition. The amoeboid phenotype has been described as rounded and irregular 
shape, with almost no focal adhesion [153]. Another group distinguish glioblastoma multiform 
cells into adherent cells and floating aggregates called neurospheres and demonstrated that mice 
injected with floating cells died 10 days faster than the mice with injected with adherent cells 
[154].  
Axl activation by its ligand Gas6 may be influenced by the presence of vitamin K. Vitamin K 
works as the cofactor for enzyme GGCX, which as previously described carboxylates the Gla 
domain of Gas6 to activate it (see section 1.6). Thus it is likely that Axl is more frequently or 
strongly activated in the presence of vitamin K [86] and this might drive the observed phenotype 
of amoeboid transition. Future studies using these Axl knock out cell lines and inhibitors are 
needed to confirm that this effect is Axl mediated.   
Our study further focused on five NZM cell lines with variable expression levels of AXL. The 
selected cell lines were cultured with and without vitamin K and treated with BGB324 a 
selective inhibitor of Axl kinase activity. Culturing cells in medium supplemented with vitamin 
K resulted in gene expression changes. These effects were maintained when the cells were 
treated with BGB324 only if vitamin K was present. For example, AXL, ZEB1, SLUG and N-
CADHERIN were upregulated in a number of cell lines cultured with vitamin K and remained 
increased with BGB324 and vitamin K. We hypothesize that when cells were cultured with 
vitamin K, Gas6 is carboxylated and activates Axl cell signaling. As BGB324 blocks Axl 
signaling it appears that the presence of excess vitamin K may overcome some of the effect, 





We did not see evidence for epithelial to mesenchymal transition (EMT) in all cell lines. This 
included plasticity markers like vimentin, Zeb1, Zeb2, Slug, N-cadherin  that  are known to be 
associated with Axl [100, 155]. Melanoma are not an epithelial type of cancer and are perhaps 
already in a mesenchymal state as can be seen from high VIM expression in almost all the cell 
lines (Figure 24).  However we did see a further upregulation of vimentin and Slug with vitamin 
K treatment in NZM 4 and NZM 34 that have high expression Axl with vitamin K but also 
NZM 3, a cell line with almost no Axl expression. This indicates possibility of vitamin K 
mediated EMT that is mediated independently of Axl. N-cadherin is another mesenchymal 
marker found to be upregulated in cancer [156] that we see increase with the vitamin K but not 
with BGB324 treatment. 
NFIX a transcription factor master regulator of the cancer metastasis linked to the upregulation 
of GGCX in lung cancer [151].  No changed in expression of NFIX were observed with vitamin 
K or BGB324 suggesting that the effects we see are directly on genes of interest. No significant 
difference in MITF transcripts was observed with vitamin K and BGB324 treatment but due to 
the complex posttranslational regulation of MITF and its isoforms, expression at the protein 
level should be investigated [48]. In the trial run of NZM 7 cell line using CyTOF, also found 
the upregulation of Axl, Vimentin and phospho-ribosomal protein S6 kinase (p-S6) and 
downregulation pErk1-2, pNF-kB, p-PLCγ2 with vitaminK treatment. Although it must be 
noted the expriment was done once as a trial run and further optmisation of parameters are 
needed.  
 
5.4 The effect of vitamin K on cell migration, proliferation and spheroid formation 
Assays were conducted to investigate the vitamin K on cell migration, proliferation and 
spheroid formation, NZM cell lines were generally found to proliferate slower, but migrate and 
form spheroid faster when cultured in vitamin K. Bilamdzic et al showed that the faster 
spheroids forming cancer cells have more invasive capacity [157]. After that, several 
contradictory papers show that spheroid formation either induces cancer progression or inhibits 
tumor growth. In spheroids, the individual cells are not distinguishable by low resolution 
microscopy such as that of the IncuCyte. Studies have shown that cells in a spheroid make 
adherens junction using E-cadherin which makes them less mesenchymal as well as less 
invasive [158]. However, the vitamin K effects on spheroid formation remain unclear. In our 





3D stay in close proximity creating an anaerobic condition tumor microenvironment leading to 
increased hypoxic response element (HIF-1 and HIF2). The increase formation of HIF1 and 
HIF2 mediate the upregulation of Axl [116, 159]. The vitamin K treated cell lines might have 
higher Axl expression than the untreated cells casing them to form spheroids faster. Expression 
of Axl in the fast forming spheroids can be determined by western blot or even CyTOF.  
In our study, we demonstrated that the NZM cell lines cultured in vitamin K proliferate slower. 
A previous study in human hepatocellular carcinoma (HCC) showed the addition of synthetic 
vitamin K in the cell culture media reduces the cell growth and proliferation. They also mention 
that the vitamin K have distinct pathway of growth inhibition than the TGF-β1 mediated 
inhibition mechanism [160]. Other studies on muscle cells explain the importance of vitamin K 
in muscle cell proliferation [161]. Previous studies mostly reported the effect of vitamin D in 
cancer metastasis. One study demonstrates the inhibition of colorectal cancer cell proliferation 
by vitamin K2. They explains the mechanism of vitamin k2 blocking the EGFR mediated 
signaling pathway followed by cell proliferation of cancer cells [162].   
We observed that cells cultured in vitamin K migrate faster. Previous studies have reported the 
involvement of TAM receptors in cancer cell migration. It was showed that the Axl 
upregulation correlates with the overexpression of the migration-associated genes like cell 
adhesion molecules (VCAM1, ICAM1 and E-selectin), integrins (ITGA and ITGB), neuropilins 
(NRP1 and NRP2) [163]. Since vitamin K is impotant for Axl activation, it was expected to 
increased cell migration with vitamin K treatment. One study demonstrated the BGB324 







6 Concluding remarks  
In this study, we have characterized the expression of Axl Gas6, other plasticity and vitamin K 
related genes in a large panel of 20 cell lines derived from patients with metastatic melanoma. 
We have looked at whether these genes could be important diagnostic or prognostic markers, 
and whether vitamin K allows melanoma cells to develop plasticity and chemo-resistant 
phenotype.  
Although we need to look at a larger sample size in the futurw, there is some indication that 
expression of the vitamin K dependent enzyme GGCX, correlated with poor prognosis. 
We also found that in addition to observing morphological differences, cells cultured in vitamin 
K alone did have an effect on the expression of Axl, its associated genes as well as other 
plasticity markers, and this effect was abrogated by BGB324. However BGB324 was not able 
to abrogate this effect if the cells were cultured in vitamin K suggesting acquisition of a resistant 
phenotype.  
In addition, function studies indicated that vitamin K tended to reduce melanoma cell 
proliferation, but increased rates of cell migration and spheroid formation, both indications of 
plasticity phenotype. Further work using the Axl inhibitors and knockout experiments are 
needed to confirm whether these functional effects are Axl mediated or whether a new pathway 
facilitating the effect of vitamin K is to be explored.  Nevertheless, we can conclude an effect 
of vitamin K that warrants further investigation. Studies on various pathways using CyTOF are 






7 Future perspective 
In our study, we indicate that the expression of GGCX correlate with poor prognosis in 
melanoma. However, Axl and Gas6 do not share the same association in melanoma. It is likely 
that the expression profiles of these genes are different in vitro and have changed over the long 
periods in culture. It is likely more useful to look at expression of these genes in resected tumors 
rather than cell lines. This is a possibility considering the current melanoma trial with BGB324 
- combination therapy at Haukeland University Hospital.  As previously mentioned, mass 
cytometry (CyTOF) analysis is also being carried out on all 20 the cell lines to assess their 
signaling profiles in vitamin K, the effect of the Axl inhibitor BGB324 in this context and also 
the effects on signaling when these cells are made resistant to BRAF inhibitors. Future 
perspectives also include using CyTOF to study tumour immune interrelations under these 
conditions.  
We also want to measure vitamin K concentration in the media, systemically in humans and in 
organs of mouse models. This is currently underway in collaboration with NEFES and 
Haukeland University Hospital.  
In the future, it would also be useful to isolate and analyze the floating cells in the media after 
vitamin K treatment and for their expression profiles to be determined separately.  
A more comprehensive and high throughput approach to studying transcription is also needed 
and samples from all these cell lines with various treatments are currently being prepared for  
RNA sequencing.  
We found that vitamin K not only effected expression profiles of cells but also their 
proliferation, and migration and spheroid formation ability. However, we need to determine 
whether this effect is Axl mediated. This might be done by inhibiting or knocking out Axl using 
BGB324 or CRISPR technology respectively.  
Finally, in vitro effects must be validated in vivo and this too is currently underway in the Prof. 
Lorens laboratory.  In vivo analysis will also help us to gain insight into the effect these 
conditions have on immune interaction and evasion.    
Other future directions include quantification and validation of bands in western blots, 
validation of spheroid formation assays using 4x magnification rather than 10X on the 





phospho status of Axl and the γ-carboxylation status of Gas6 using immunoprecipitation by 
ELISA or western blot. Co-immunoprecipitation might also be used to study the interstation of 
Axl with Gas6 and other proteins.  
Several studies showed using mass spectrometry that the auto phosphorylation of Axl upon 
ligand Gas6 binding can be occur in several site. Almost six sites were demonstrated at the 
autophosphorylation site that have no downstream effect. The mostly active phosphorylation 
site of Axl are the Y779, Y821, Y866 and these sites are the docking site for critical signaling 
cascades [165, 166]. Sandwich ELISA based assays looking at the effects of vitamin K and 
BGB 324 on Axl phosphorylation at position of Y821 and Y866 were attempted but data has 






8 Supplementary Figures  
 
 
Figure 36: The correlation of clinical outcome with expression of AXL, GAS6, GGCX and VKORC1. 
The graphs showing only the significant results. The significance was determined using the Pearson r 
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